Explore every episode of the podcast Diabetes Connections | Type 1 Diabetes
| Title | Pub. Date | Duration | |
|---|---|---|---|
| Looking back on 2025: Hype, hope and what really matters, with Neil Greathouse | 30 Dec 2025 | 00:56:27 | |
This week on Diabetes Connections, a conversation about what really matters in diabetes. We're talking about the top stories of 2025, the hype that didn't happen, some trends for 2026, what community can accomplish, and what LeBron James has to do with all of this. We also get personal – because I'm being interviewed by the wonderful Neil Greathouse, host of Your Best T1D life, and so much more. This episode contains a replay of Your Best T1D Year. Check out Neil's great podcast! This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) All about VIVI Cap to protect your insulin from extreme temperatures
| |||
| Do We Need an At-Home A1C Test in the Age of CGM? Orange Biomed Says Yes | 26 Dec 2025 | 00:22:45 | |
Making the case for a better at home A1C test. Orange Biomed is developing a compact, one-drop, at-home A1C testing device they say could make frequent A1C checks easier and more accessible than ever. They're passionate about closing the gap for people who struggle to get to clinics regularly… and the research they share is compelling: four A1C tests a year can lead to a nearly 4% reduction in A1C levels. We'll talk about why more frequent A1C monitoring matters—even in the era of continuous glucose monitoring—how their new device works, and what early clinical trial results look like. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More about Orange BioMed here Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com
Episode transcript:
Stacey Simms 00:05 Today on diabetes connections, making the case for a better at home A1C test. Orange biomed is developing a compact, one drop device that they say could make frequent A1C checks easier and more accessible. They're sharing research that four A1C tests a year can lead to a nearly 4% reduction in A1C levels, but they say a lot of people can't get to the clinic that much. We'll talk about why this matters, even in the era of CGM, how the device works and what the early clinical trial results look like.
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your healthcare provider.
Welcome to a bonus episode of diabetes connections. I hope your December is going well and that you know somehow you're able to take some time for yourself in the middle of all the holiday rushing around this time of year can be magical and stressful and exhausting and wonderful, and you know, all the things. And it's the same thing over here, super busy getting all this stuff done before the end of the year. Love it. But, you know, getting podcast episodes out, writing all the things we write and planning for next year, as they say, We're staying booked and busy.
But quick behind the scenes here to better explain this episode, I taped this interview way back over the summer during the ADA Scientific Sessions conference. I had some technical problems. I actually thought I lost this interview. There were two interviews that seemed to have gone missing. We're going to air the other one very soon. But thankfully, I do have backups upon backups. So all the info that you're going to hear today is still relevant.
This product, a small A1C test, is still in development. The only dated bit is about their follow up event that took place in August. Orange Biomed was launched in 2021 in South Korea, with its US headquarters in Providence, Rhode Island. Its founders are two Duke University alums, and they're my guests, CEO Yeaseul Park and Co-President Unghyeon Ko, We are also joined by Janice Dru-Bennett. She is a senior advisor at the company. Now, English is not the first language of two of these three speakers. This is a good time to remind you that most podcasting platforms have pretty good transcription services these days, especially Apple, I think they have a fantastic real time transcription service for podcasts that has been impressive to me in how they translate diabetes language. They're getting better at it. But I am also going to put a transcript of the interview in the show notes, which I don't normally do because the podcast services have gotten so good at it, but I think it could be helpful for at least a few of you out there. Okay, here is my conversation from the floor of ADA from the team at Orange biomed.
Yeaseul Park, Janice Drew Bennett and Dr Ko, Welcome to diabetes connections. I can't say live from ADA, because we're taping this to air later, but you're all there. Thank you so much for joining
Yeaseul Park 03:08 me. Yes, thank you. We're
03:10 excited to be here. Oh
Stacey Simms 03:11 my goodness. Can I ask first, how is the trip? I mean, yes, let me ask you. You guys came a long way.
Yeaseul Park 03:17 Yeah, it was 13 hours from Korea. But it's I'm so excited, because this event is really one of the times, and this is actually our third time attending ADA.
Stacey Simms 03:31 That's great. And we have so many questions for you, but Janice, let me ask you, you're there as everybody's setting up at the kind of beginnings of the show. What is it like right now for people who aren't familiar with ADA,
Janice Dru-Bennett 03:42 yes, you can hear the hammers in the background, although, but not on this podcast, but there's a lot of noise and people walking by. We're just setting up this the day before the exhibit hall opens and Dr Cole will be presenting at the Innovation Hub tomorrow, which is where we're sitting right now, with tables of innovators will be showcasing their diabetes innovations, and
Stacey Simms 04:04 there's a lot to get to. Dr Koh, I know you're presenting, but yes, let me ask you, like, what why? I know you said it's your third year, but why is orange biomed at ADA, what is your goal
Yeaseul Park 04:16 for us? ADA, is for a learning experience. As well as a platform to share. We come to see how all those around the world are fighting against diabetes, whether through clinical research, digital tools or technologies or community programs. At the same time, you're so proud to hear what orange biomat is building anytime, and eight months exhausting. That makes diabetes monitoring not accessible, not so many. And this year is especially exciting because Dr ko our co founder of orange buying at the group of speaking at ADA brand new program the innovation Hall.
Stacey Simms 04:58 That's awesome. So Dr Koh, tell me. Little bit about this, the Innovation Hub is pretty cool, but what are you going to be talking about?
Unghyeon Ko 05:05 Yeah, actually, I'm talking about the engineering part. I mean our technology, so our orange biomed, we are trying to solve a simple but a serious problem about the A1C accessibility. So to increase the A1C accessibility. So we are, we are developing at home device to measure the A1C level. So I'm, I'm talking about how difficult to increase the accessibility of A1C, but our technology is handled that difficult problem. So we now he's so agreed. So I'm going to introduce our technology and emphasize the importance of the A1C measurement at home.
Stacey Simms 05:49 Yeah, so A1C, it's interesting. My son was diagnosed at two, and in the pediatric world, you know, they'll just prick a finger generally and have that A1C right away. But my husband lives with type two, and he gets his labs drawn. And then it takes forever. So tell me a little bit before we go further about what you're hoping to do and making this easier for the patient,
Speaker 1 06:10 the frequent monitoring of A1C is so important to prevent the diabetic complications. So the money, so if you there is some so I can say that there is a research that if you measure the A 1d the four times a year, the People's A1C level is decreased like 3.8% but if you measure the A 1d at one per year, Then the A1C level is increased 1.5% so the frequent A1C monitoring is so important to prevent the diabetes complications. But problem is A1C measurement is only available at clinical site at this moment, so most of the A1C monitoring is done by the clinical side. So that's why people are difficult to monitoring A1C, because they have to visit the clinics forever. So is so like four times, or even eight times visit the clinics or hospital is quite difficult, especially in the people living in the far area from the hospital. So that's why the home A1C test is required. So I think that's why the accessibility of the A1C is one of the important things in managing the diabetes complications.
Stacey Simms 07:39 Dr Koh, is there evidence that, I mean more frequent A1C testing, I think would give many people peace of mind, perhaps. But is there evidence that it really does help in your health?
Speaker 1 07:51 Oh, yes, it is actually like from there is the research, like the famous research about the A1C level, like the research name this t and this research proved that the A1C is the one of the strongest predictor of diabetes complication. So A1C is completely related with the risk of diabetes complication. So like keeping A1C on the 7% dramatically lower the risk of diabetes complications. And also, there is another research in UK, the UK PDS study, and that study said they are A1C. Lowering A1C by just 1% can reduce overall mortality by 15% and microvascular complication by 37% so the roaring A1C is the goal of the treatment of the
Yeaseul Park 08:47 diabetes. So
Stacey Simms 08:48 when I think of at home diabetes tests, blood tests, seem like they're they're really sensitive, right? You have to be very careful with things like that, although we do, we did finger sticks at home for years and years. Are there challenges with at home A1C testing that that people like me could mess up,
Yeaseul Park 09:06 sure actually when I was doing pandemic outside system? So it's a new
Yeaseul Park 09:19 box of mustard with five or six needles inside, and we need to collect this blood to sound the left result. But then I really tried to collect the requirement matter blood, which is like it was like bleeding. Oh, it's not just retiring in one block, one drop of block, but it's like you need to try, yeah, many times, not just in one spot, to collapse in the block. And the other way you. Built female in, built a lot more broadly, to store your venous blood, and that's features like discomfort.
Stacey Simms 10:10 Would you mind taking us through your experience with the A1C testing? You were talking about how much blood it took? Yeah.
Yeaseul Park 10:17 So it, it requires many, many drops of blood. So I felt like it's like bleeding, and you make a lot of mess around the table. And so I felt, even though it's it was a topic time it was pandemic. So that's the only option I had at that time, but I wanted to make it simple and easier. And the other types of point of care devices only use a drop of blood still have some limitations, because we all don't want to bleed too much, so sometimes we try to finger stick very small and just squeeze to get enough blood. But if you squeeze to get enough sample volume, that's make your other liquid, like sweats, can also mix with your blood, and that actually affects the accuracy of the testing usually so many point of care devices also not recommend you to squeeze to get enough blood, so that means you need to treat a little too deep to get enough. So we really wanted to make this whole process or simpler and more problem.
Stacey Simms 11:43 Can you share a little bit about what the device looks like, what the patient experience is when they use it?
Speaker 1 11:48 Dr, CO, so our device is a palm size. Is in most like, like self, self poem, so it's a palm size device. So our device has no switch, but there is only a slider in the front of the device. So if you slide that, you can the device is turned on and you can insert the cartridge, and the cartridge is disposable cartridge. So after that, you just collect your blood and dilute it in the collecting tube and drop the sample into the cartridge, then analyze the A1C like automatically. So it's quite similar with the covid by covid test kit. So the covid test kit collect the sample in your nose and mix with the Rickett and drop it right? And it's quite similar.
Stacey Simms 12:45 So do you do a finger stick to put on the cartridge? How much blood to yells? Point, you know? How much blood do you need?
Speaker 1 12:52 Our devices for home use device, so it's quite we use a very different technology, because our device analyze the red blood cell one by one. So actually, we don't need exact unlike like five micro or 10 micro, we don't need the exact sample block. So we just need one drop of blood. So if the one drop is big, or if the one drop is right or small, it's fine for us. So one drop of blood, mix with their sample and drop one drop onto the cartridge. So maybe you can, you can drop one more than one drop, but we recommend one drop. So one drop of blood sample my dinner the rest yesterday pointed out that the skeezing the finger of blood is a problem for other device because, because in our body, there is a body wicked inside your under, under your skin. So if the body wicked is mixed with the blood samples, so it might be a problem because it dilute the blood sample. But our device, we analyze the Red Cross itself. So if it is diabetes, I think so we will find so you just puncture very best, and if you scale it, and it's totally fine for us. So it's, it's one of the good point of our device.
Yeaseul Park 14:20 How long does it take to get the results? It takes like, five minutes. Okay, yeah, and that's all at home. Yeah. Yezel, who do you see using this? Who is this for? Basically, it's for everyone. I think whoever has pre diabetes, diabetes type one, type two, and especially, I think who has limited access to primary care or lab testings. You know, many people who are older, tends to have more, especially the people who has limited access to primary care or lab testings. We believe this device can give more value to them. Yeah, and especially some people who have limited mobility, if they are older, or if they have experienced that amputation or something like that, they cannot go to the hospital by themselves. They need a caregivers to drive them to the hospital for the simple lab testing. But now I think it empowers patients who has that limitation still can take control their health by using this kind of home use device. How accurate
Stacey Simms 15:33 is it? I assume you have studies, and you've done some trials on how on the accuracy?
Yeaseul Park 15:37 Dr, CO, do you want to add that?
Speaker 1 15:40 Oh, yeah. So we are preparing the clinical trial. So the official clinical trials will be done within this year, but so that's our plan. But we we tested our device already using the in in last year. So last year, feasibility studies show that our device is quite similar with other point of care devices, and hopefully because at that time, our device, our especially our cartridge sensor, we just manufacturing our own like our in our lab. So this time, the official clinical trial in in this year, we are going to manufacturing in the factories so it might be more precise. So we hopefully we trying to chase the hospital accurate.
Stacey Simms 16:30 And I have to ask, where more and more people with diabetes are wearing a CGM and looking at time and range. What would you say to people who would tell you, well, we don't really need A1C anymore. We have time and range. Dr Cody, I see you nodding. Go ahead, yeah, yeah.
Speaker 1 16:47 So that's a very important point, but because the timing range is also important, and the CGM is very great technology for diabetes people. But problem is, like the A1C and C GM target different, like the CGM target the hypothesemia, but the A1C targeting the diabetes complications. So like, if you measure the timing range and you can manage your average glucose more nicely, but it might be prevent your hypothenia. But if you want to assess your diabetes management, you might be measure A1C. So if you measure timing range, but you also have to measure the A1C. So A1C is for everyone's and so. And also, the point is, if you don't treat the insulin, or if you don't treat the any medications, then you don't need to actually using the CGM, that's the ADH recommendation. So, but in in that case, you need the A1C as well. So A1C for everyone, and the CGM is for the people who treated the insulin. That's the ADA guide, right? And then,
Stacey Simms 18:12 yes, let me just ask you. You know, you came all this way. As you say, this is your third time at ADA. Trials are starting soon. What's your hope here? Is this something you see in homes of everyone who has any kind of diabetes? What's the big goal for Orange biomed?
Yeaseul Park 18:28 Every time we talk to a day, we can feel what's going on here in diabetes industry. It's a huge maybe first year, I the most frequently hard keyword was aid system. But after that, we now have GLP one, and now we hear more keyword around obesity. So that's a little slightly different trend I can feel. And once you come and join this full sessions, then I can see there's make everyone is making a progress, and we are all together. Want to fight against diabetes in their own way or with their own expertise, whether it's pharmaceutical, whether it's medical device or diabetes, sex, sometimes any other community programs that really support this patient and families, the community, and it's Really this whole atmosphere actually really motivates our team and myself, and we can feel the value. I can really feel this we are doing something valuable to patients and our community, and that's the most great thing, like the greatest thing that I can take when I come back to home with a. After the ADA. And for sure, we want to have opportunity to make voice what we are doing at Orange biomed, and want to deliver this value to the patient and other healthcare professionals. Otherwise, even though we are working hard to make this progress, no one knows, and that makes any changes the world. So that's the important purpose we are coming here. That's great.
Stacey Simms 20:30 Janice, before I let you all go, I know you wanted to talk about an event you've got coming up in Chicago. Can you tell me a little
Janice Dru-Bennett 20:37 bit about that? Yes, we're really excited for Orange biomed to be hosting the first map your health event, a local event here in Chicago, we have done a solving healthcare challenges webinar to announce our map your health campaign, which is, monitor your A1C, monitor your health and then adapt your treatment and prevent chronic disease. And we're actually going to be hosting on August 16, from 10am to 3pm in Chicago at their humble Park, Health Wellness Center, the first local event, inviting all local partners. We'll have some virtual sessions, showcase with yoga or ask the endocrinologist. So we'll have a very exciting agenda that both virtual and on site participants can join in, eat healthy foods. See, see what's in Chicago from a screenings perspective, and really get people motivated to map your health. So hashtag, map your health. Tell your your your health story, and let's get everyone, um, healthier. Wow.
Stacey Simms 21:35 Okay, fantastic. Well, yes, I'll park Dr co Janice, thank you so much for joining me. Have a terrific show. I know this is an audio podcast, but especially behind you. Yassil, it has been wild to watch the construction guys are going by and motorized carts and things are going up behind you. So have a wonderful ADA. Keep us posted, and we'll get the word out about your event in August and going forward. Thanks so much for joining me.
more information in the show notes about the studies and about orange biomed. You can sign up for alerts and emails from them as their product moves forward. So if you're interested, definitely check that out. Thank you to my editor, John Bukenis from audio editing solutions, thank you so much for listening. I'm Stacey Simms. I'll see you back here soon. Until then, be kind to yourself.
Benny 22:30 Diabetes Connections is a production of Stacey Simms media. All Rights Reserved, all wrongs avenged.
| |||
| Inside Tandem's Latest: catching up with VP of Product Management Marisa Fienup | 11 Nov 2025 | 00:37:51 | |
We've got an update from Tandem Diabetes. We're talking about Libre 3 plus integration, Lyumjev approval, Mobi tubeless, extended wear infusion sets and a lot more with VP of Product Management Marisa Fienup. She's also answering your questions about tubing, alerts, and shares what's next. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Information on RocketAP and other closed loop research Tandem earnings call info here Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections. | |||
| Travel Alert: What You Need to Know About Geofencing and Dexcom G7 | 03 Sep 2024 | 00:31:53 | |
Traveling with diabetes gives you enough to think about – especially traveling internationally: preparing, packing, going through airport security. But if you travel out of your country – not just the US – with your Dexcom G7, you also have to be aware of something called geofencing. If something goes wrong with your phone or your app.. getting it back is going to be an issue. We'll talk about how this works, why it's in place, and what you can do about it. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out - registration is open for Denver and Philadelphia! More from Loop & Learn: https://www.loopnlearn.org/g7-geofence/ Stacey's free travel guide and packing list: https://bit.ly/DiabetesCxnsTravel Previous episode with Dexcom's Jake Leach Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections. | |||
| In the News.. Omnipod 5 approved for type 2, bright light at night diabetes link, Zepbound price cut, and more! | 30 Aug 2024 | 00:08:58 | |
It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: The FDA approved Omnipod 5 for people with type 2 who use insulin, Dexcom's Stelo, the first over the counter CGM, is now on sale. more evidence that bright light at night may increase the risk of diabetes, a price cut for Zepbound, and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:
Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In a first for any automated insulin delivery system, The FDA clears Omnipod 5 for people with type 2 diabetes. The new indication is based on data from the real-world multicenter SECURE-T2D trial of a racially diverse group of 305 adults with type 2 diabetes who were taking insulin. About half were also taking a glucagon-like peptide-1 (GLP-1) receptor agonist. Use of the Omnipod 5 resulted in a significant A1c reduction from 8.2% at baseline to 7.4% at 13 weeks (P < .001), with no differences in outcome by GLP-1 receptor agonist use. Some doctors are already prescribing the Omnipod 5 off-label to some of their patients with type 2 and other types of diabetes. Private insurance will typically cover it, although prior authorization is often required. Medicare Part B requires certification of C-peptide deficiency for coverage of insulin pumps. This new indication is likely to increase uptake of the Omnipod 5 into primary care, where the vast majority of people with type 2 diabetes are managed. https://www.medscape.com/viewarticle/fda-clears-omnipod-5-system-type-2-diabetes-2024a1000fld XX For the first time, you can get a CGM over the counter, with no prescription. Dexcom began selling Stelo this week.. intended for people with Type 2 diabetes who don't take insulin, although it can be used by people without diabetes. It costs 99 dollars for a one-time order of two sensors or $89 dollars for a monthly prescription. Stelo is a 15-day sensor based on Dexcom's other glucose monitors. The main difference from prescription products is in what information users get through the app. Stelo flags glucose spikes, provides information on time-in-range goals, and includes meal and activity logging. The intent is to reveal how food, exercise and sleep can affect a person's glucose levels. Competitor Abbott plans to launch two over-the-counter CGMs: one called Lingo, for people without diabetes, and one called Libre Rio, for people with diabetes who don't use insulin. It has not yet priced either sensor. Abbott said it plans to debut its competing Lingo device this summer. The company has not said when it will launch its Rio CGM. https://www.medtechdive.com/news/dexcom-sells-stelo-over-the-counter-cgm/725310/ XX You'll soon be able to get vials of Lilly's popular weight loss drug, Zepbound, from a direct to consumer website, at a lower cost. This is still nearly 400 dollars a month for the lowest dose $550 for the next lowest and it will come in vials, not pens. Lilly and Novo have been struggling to make enough of their obesity medications to meet soaring demand, especially keeping up the pen supply. Lilly's medicines are now listed as available by the U.S. Food and Drug Administration, though they are not yet off the FDA's official shortage list where they have been most of the year. I haven't seen this mentioned in any of the reporting but.. if it's coming in a vial, you have to use a syringe to inject. Not much of a barrier to this group listening.. but pens have made using drugs like this much easier for a lot of people and I worry that going back to syringes is better for these companies than the patients. Zepbound is terzepatide, the same mediation as in Mounjaro. The latter is approved for people with type 2 diabetes, so this could be a way for some people to better access Mounjaro which is very hard to come by. https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-launches-single-dose-vials-zepbound-weight-loss-expand-us-supply-2024-08-27/ XX In a few months the US govermet will announce the list of 15 moe drugs they'll negotiate Medicare prices for.. and Ozempic is a top candidate. This is speculation from Wall Street analysts but I think worth watching. All the drugs on their prediction list have been on the market since at least 2017 and are among those that the Medicare health program spends the most on. Under President Joe Biden's signature Inflation Reduction Act (IRA), prices for 10 highly popular prescription drugs used by Medicare will be cut by 38% to 79% in 2026. The industry has fought the negotiation program, saying it will stifle innovation. Government researchers predict that the use of diabetes drug Ozempic for weight loss would raise the U.S. deficit over the next 10 years at its current price. Medicare spent over $4.6 billion on the drug in 2022. https://www.reuters.com/business/healthcare-pharmaceuticals/ozempic-wall-streets-list-2027-medicare-drug-negotiations-2024-08-23/ XX Type 2 diabetes and prediabetes are associated with accelerated brain aging, according to a new study from Karolinska Institutet in Sweden published in the journal Diabetes Care. The good news is that this may be counteracted by a healthy lifestyle. Type 2 diabetes is a known risk factor for dementia, but it is unclear how diabetes and its early stages, known as prediabetes, affect brain aging in people without dementia. Now, a comprehensive brain imaging study shows that both diabetes and prediabetes can be linked to accelerated brain aging. The study included more than 31,000 people between 40 and 70 years of age from the UK Biobank who had undergone a brain MRI scan (magnetic resonance imaging). The researchers used a machine learning approach to estimate brain age in relation to the person's chronological age.
Prediabetes and diabetes were associated with brains that were 0.5 and 2.3 years older than chronological age, respectively. In people with poorly controlled diabetes, the brain appeared more than four years older than chronological age. The researchers also noted that the gap between brain age and chronological age increased slightly over time in people with diabetes. These associations were attenuated among people with high physical activity who abstained from smoking and heavy alcohol consumption. https://medicalxpress.com/news/2024-08-healthy-lifestyle-counteract-diabetes-brain.html XX
Edgepark Commercial XX Another study showing the link between bright light at night and a higher risk of developing type 2. This study in the journet Lancet In the large modeling study, the research team investigated whether personal light exposure patterns predicted the risk of diabetes using data from approximately 85,000 people and around 13 million hours of light sensor data. The participants – who did not have type 2 diabetes – wore devices on their wrists for one week to track their light levels throughout the day and night. They were then tracked over the following nine years to observe whether they went on to develop type 2 diabetes. "Light exposure at night can disrupt our circadian rhythms, leading to changes in insulin secretion and glucose metabolism," he says. Having more exposure to light at night (between 12:30 am and 6:00 am) was linked to a higher risk of developing type 2 diabetes, and this was true regardless of how much light people were exposed to during the day. The research accounted for other factors associated with type 2 diabetes, such as lifestyle habits, sleep patterns, shift work, diet, and mental health.
Even after taking these factors into account, the findings showed that getting more light at night was still a strong predictor of developing diabetes. https://scitechdaily.com/scientists-discover-simple-and-cheap-way-to-reduce-your-risk-of-diabetes/ XX Is there a link between voice pitch and glucose levels? And is it strong enough to one day perhaps lead to non-invasive glucose monitronig? Klick Labs published a new study in Scientific Reports today—confirming the link In "Linear Effects of Glucose Levels on Voice Fundamental Frequency in type 2 diabetes and Individuals with Normoglycemia," researchers investigated how blood glucose levels influence the frequency of the voice in 505 participants across three glycemic statuses—non-diabetic, prediabetic, and type-2 diabetic. Participants were fitted with continuous glucose monitors (CGMs) and recorded their voices multiple times daily for two weeks. The analysis revealed a linear relationship where an increase in CGM glucose levels corresponded to an increase in the fundamental frequency in the voice. The lead author says, "Whereas current glucose monitoring methods are often invasive and inconvenient, voice-based glucose monitoring could be as easy as talking into a smartphone, which could change the game for the estimated 463 million people around the world living with type 2 diabetes."
Klick Labs' latest research marks another step forward in its ongoing commitment to advancing the detection and management of diabetes using voice tech and machine learning. Their October 2023 study in Mayo Clinic Proceedings: Digital Health demonstrated that voice and AI can screen for type 2 diabetes with high accuracy.
https://medicalxpress.com/news/2024-08-diabetes-links-blood-glucose-voice.html#google_vignette XX Earlier this year we talked to the teenager behind a free bolus calculator. The FDA took T1D1 down, when they and Apple started cracking down on health tools without regulatory approval. Drew Mendalow has been working to bring it back and we have an update: He says, "Over the last two years, we have been tirelessly working to complete our FDA premarket submission. Thanks to contributions by the T1D community, we were able to complete the preparations needed for the Human Factors Study. The trial itself is the last, vital piece needed before we can submit the app to the FDA. Now, we're thrilled to announce that the team at Dexcom has graciously offered to run the study for us!" It's a big deal – kudos to Dexcom and to Drew. We'll let you know when T1D1 is back in the app store. XX Join us again soon! | |||
| Why Medtronic and Abbott are teaming up - and what it means for you | 27 Aug 2024 | 00:25:35 | |
Medtronic and Abbott are joining forces – and we have questions. The announcement that Abbott will create a new CGM, based on the Freestyle Libre, exclusively for Medtronic comes just as Medtronic gets FDA approval for it's newest sensor. So why the team up? Why now? And what will all this look like for the person using these systems? We're talking to both companies. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out - registration is open for Denver and Philadelphia! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections. | |||
| Kicking down barriers: Chris Bright is inspiring the next generation of athletes with T1D | 20 Aug 2024 | 00:37:22 | |
It's hard to believe that a generation ago, doctors were still telling newly diagnosed people that they shouldn't play sports with type 1 diabetes. My guest – Chris Bright – is not just an example of how wrong that thinking was and is.. he's actively now helping others pursue their dreams with T1D. Chris was diagnosed as a child back in 1999 and is the founder of The Diabetes Football Community. Chris shares his early challenges, how his mother's experience with type 1 affected their family, and what he wants you all to know about playing any sport with diabetes. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out - registration is open for Denver and Philadelphia! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections. | |||
| In the News... weekly basal + semaglutide, liver targeted insulin, Lance Bass educates about LADA, and more! | 16 Aug 2024 | 00:07:15 | |
It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: A weekly basal plus semaglutide is in the works, but not for the US right now, Tandem updates it's app recall, liver targeted insulin study, a weird walking story, and Lance Bass educates about LADA. Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Novo Nordisk moves ahead with a new combination: once-weekly insulin icodec and semaglutide. Called IcoSema, Novo plans to submit for approval in Europe, Canada, Japan and Australia but NOT the US. As we told you earlier this summer, icodec – once weeky basal insulin – was not approved by the US FDA. Semaglutide is the molecule underpinning Novo's immensely popular GLP-1 drugs Ozempic and Wegovy. Icodec has been approved as Awiqli in places like Europe, Canada, Japan and Australia but was snubbed by the FDA last month. The FDA has left the door open for another application, but Novo says they don't expect to iron it out this year. In studies, the combination worked well to lower A1C for people with type 2 and they lost weight. They also had fewer lows. https://www.fiercepharma.com/pharma/corrected-after-icodec-rejection-novo-nordisk-wont-file-application-once-weekly-insulin-and
XX An update from Tandm on their app recall. Back in March they notified users of the recall because of an issue that can cause rapid depletion of a user's t:slim X2 insulin pump battery. This battery depletion can result in the pump shutting down sooner than expected, which some customers have continued to experience even after an updated version of the app was released. Notices were emailed to impacted customers on August 9, 2024 with updated information and recommendations for helping avoid pump battery depletion. Tandem plans to release a new version of the app to address the remaining issues and will notify all users by email and app push notifications following its release. Impacted customers in the U.S. with questions about this recall can contact the Tandem Diabetes Care Technical Support Team 24 hours a day, 7 days a week at techsupport@tandemdiabetes.com or (877) 801-6901. https://www.businesswire.com/news/home/20240812040222/en/Tandem-Diabetes-Care-Provides-Update-on-March-2024-Nationwide-Recall-of-tconnect-Mobile-App-for-iOS-Devices XX If you are an adult who has type 1 diabetes, you may be eligible to participate in a trial examining the impact of an investigational liver-targeted insulin on blood glucose control, A1C, and nighttime lows. This study is researching whether administering a liver-targeting insulin called HDV-L insulin (Hepatocyte-directed Vesicles-insulin lispro), will improve glycemic control. HDV-L insulin is designed to act on the liver to enhance glucose storage and decrease the frequency of severe hypoglycemia in individuals requiring insulin. It is not currently approved for use. For this trial, researchers are recruiting roughly 230 adults with type 1 diabetes aged 18-79 who are on multiple daily injections (MDI). This study is recruiting in California, Colorado, Florida, Georgia, Illinois, Indiana, New York, North Carolina, Ohio, and Texas. To enroll or learn more about this study, contact Todd Hobbs, MD at Diasome Pharmaceuticals at thobbs@diasome.com or call 216-780-9324. Clinical Trials Identifier: NCT06238778 https://diatribe.org/diabetes-research/new-study-tests-liver-targeted-insulin-type-1-diabetes XX Sanofi is investing heavily to boost insulin production. They opened a new facility in Germany for the basal insulin Lantus and they announced they will invest over one billion dollars to expand production capacity in France. Sanofi's considerable investment in insulin production is especially important given that other insulin companies appear to be focusing their efforts on production of GLP-1 medications like Mounjaro and Ozempic, rather than insulin. This has left some patients worried that Novo Nordisk and Lilly will leave them behind to pursue more lucrative products for weight loss, especially after Novo Nordisk decided to discontinue the basal insulin Levemir. https://diatribe.org/diabetes-medications/sanofi-build-new-state-art-insulin-plant
XX Hoping to talk to Abbott and Medtronic soon about their partnership announced earlier this month. The companies announced that Abbot will create an integrated continuous glucose monitor that works only with Medtronic's diabetes technology and be sold exclusively by Medtronic. Along with announcing the partnership, Medtronic said Wednesday it received FDA approval for its Simplera CGM, which does not require fingersticks or overtape, unlike the company's previous sensors. The Simplera Sync sensor, which is designed to work with Medtronic's automated insulin delivery algorithm, is under FDA review separately. https://www.medtechdive.com/news/abbott-medtronic-partnership-automated-insulin-delivery/723600/ XX Researchers have developed a novel computer algorithm that can predict various diseases like diabetes or stroke, just by analysing the colour of the human tongue with 98 per cent accuracy. The imaging system developed by Middle Technical University (MTU) and the University of South Australia (UniSA) in Australia can diagnose conditions such as diabetes, stroke, anaemia, asthma, liver and gallbladder issues, Covid-19, and other vascular and gastrointestinal diseases. "The colour, shape, and thickness of the tongue can reveal a litany of health conditions," said Ali Al-Naji, adjunct Associate Professor at MTU and UniSA. The paper published in Technologies describes how the system analyses tongue colour to provide real-time diagnoses, demonstrating that AI can advance medical practices significantly. The breakthrough was achieved through a series of experiments using 5,260 images to train machine-learning algorithms to detect tongue colour. Researchers received 60 tongue images from two teaching hospitals in the Middle East, representing patients with diverse health conditions. The AI model matched tongue colour with the correct disease in nearly all cases. https://www.ndtv.com/world-news/new-algorithm-analyses-tongue-to-predict-diabetes-stroke-with-98-accuracy-6327124 XX Big roundup article from the UK Guardian all about 6 projects all around smart insulin. Not a lot new here, but it caused a lot of chatter. I'll link it up – good summary of all of the research happening in the space right now. Glucose-responsive insulin is the idea that you could give one injection and the insulin would respond to the rise and fall of glucose levels without further action by the person.
https://www.theguardian.com/society/article/2024/aug/11/scientists-hail-smart-insulin-responds-changing-blood-sugar-levels-real-time-diabetes XX Edgepark Commercial XX Lance Bass (like glass) continues to keep the public posted on his recent LADA diagnosis. The boy band singer showing his IG audience more about what's also called diabetes 1.5 and explaining how he was first diagnosed with type 2. XX Ok, brace yourself – I promise this is a real story. The Fart Walk is actually good for you. Ok.. stay with me. This is really just a great silly reframing of something we all know, and I couldn't resist putting it in here. A wellness influencer put this out – you may have seen it – claiming the after dinner stroll can limit your risk of type 2 diabetes. A lot of studies confirm that – along with it having benefits if you already have diabetes. The flatulence part – or a release of gastric pressure – is also a known benefit of moving more after meals. So it's funny, farts are always funny, but if it gets more people to walk after they eat I'm all for it.
https://people.com/fart-walk-benefits-what-is-it-type-2-diabetes-8694630#:~:text=Wellness%20influencer%20Mairlyn%20Smith%20has,of%20day%20you%20do%20it XX Join us again soon! | |||
| "It connects me with joy" - Meet storm chaser Jen Walton | 13 Aug 2024 | 00:42:36 | |
This week, when it's stormy out – most of us head inside. But there are those who just can't wait for big storms and extreme weather so they can head out to track and learn from it. Jen Walton is a storm chaser and photographer who lives with type 1. We'll talk about how her diagnosis as an adult helped kick off her long-delayed dream to chase, how she prepares and manages with T1D on board, and how she's encouraging other women and girls to share her passion for extreme weather. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Jen Walton's Instagram Find out more about Moms' Night Out - registration is open for Denver and Philadelphia! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections. | |||
| The journey to diabetes independence: when T1D parenting becomes "Customer Support" | 30 Jul 2024 | 00:26:27 | |
I spent a lot of this summer at diabetes conferences and the top question I got from parents was: how did we make Benny so independent with his T1D? But there are some things I've learned that may make it easier for you. I'll explain my parenting pivot to Customer Support with the release of this excerpt from "Still the World's Worst Diabetes Mom" Find out more about Moms' Night Out - registration is open for Denver and Philadelphia! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections. | |||
| Winning at the Olympics with T1D: Gold Medalist Gary Hall, Jr | 28 Jul 2024 | 00:19:29 | |
When Gary Hall Jr was diagnosed with type 1 diabetes in 1999 his doctors told him to give up competitive swiming and drop out of the 2000 Olympics. Instead, he charged ahead and became the first person with T1D to take home an Olympic Gold Medal. Hall won Gold in Sydney in 2000 and again in Athens in 2004, adding to the medals he'd won in 1996 before his diagnosis. Stacey caught up to Gary at this summer's Friends for Life Conference and asked him how he got past what his doctors told him. He also shared what he tells newly diagnosed families today. This interview first aired in July 2021 This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out - registration is open for Denver and Philadelphia! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections. | |||
| Fast-tracking progress on a T1D treatment: All about Diamyd Medical | 23 Jul 2024 | 00:37:52 | |
We're hearing more and more about prevention of type 1 diabetes. There's some big news on that front – just last week Diamyd Medical got fast track designation for it's medication to stave off T1D for people who carry a particular gene – a gene that about 40-percent of people with type 1 have. Diamyd is recruiting for some big clinical trials – we'll find out who's eligible, where you have to go and what you to have to do, and the reasons why there's an awful lot of hope around this. My guest this week is Elna Narula, US Site Relations and Patient Recruitment Lead at Diamyd Medical. Her daughter was diagnosed with type 1 more than 30 years ago. Elna was already working in healthcare and she became a diabetes educator. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Learn about the studies and recruitment here Find out more about Moms' Night Out - registration is open for Denver and Philadelphia! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections. | |||
| In the News...Does insulin use differ by gender? T1D & Covid update, fully implantable CGM studied, and more! | 19 Jul 2024 | 00:09:21 | |
It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: A new study looks at insulin needs in men vs women, updates on stem cell transplants and a new look at COVID 19 and T1D plus a fully implantable CGM is announced. We'll also tell you about a T1D athlete drafted to the MLB. Lots more in this week's episode, full transcipt below. Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:
Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX Do men and women have different insulin requirements? A new study conducted across Europe says yes – women overall need less. Published in the Journal of Diabetes Science and Technology this looked at over 9,000 adults with type 1 diabetes using data from patients using the Diabeloop Generation 1 (DBLG1) hybrid closed-loop pump system. In this study, women needed 14-percent less insulin overall than men. These researchers say these findings have important implications for the practical management of insulin therapy and highlight the necessity of considering gender as a crucial factor in diabetes treatment. The treatment guidelines provided by American and European Diabetes Societies do not currently have gender-specific recommendations for insulin-weight ratios. The co-founder and Chief Scientific and Technical Officer for Diabeloop. "This study also highlights the capacity to discover new insights from big-data analysis of real-world data." *Insulin Requirements According to Gender and Weight in a Population of 9036 Adult Persons With Type 1 Diabetes Using Closed-Loop Insulin Delivery, https://doi.org/10.1177/19322968241252366). https://www.theglobeandmail.com/investing/markets/markets-news/GetNews/27419187/diabeloop-study-reveals-significative-gender-differences-in-insulin-requirements-for-type-1-diabetes-patients/
XX New drug therapy in those lucky diabetic mice boosted insulin-producing cells by 700% over three months, effectively reversing the disease. Scientists at Mount Sinai and City of Hope have been able to grow new beta cells in the body, in a matter of months. The therapy involved a combination of two drugs: one is harmine, a natural molecule found in certain plants, which works to inhibit an enzyme called DYRK1A found in beta cells. The second is a GLP1 receptor agonist. The latter is a class of diabetes drug that includes Ozempic, The researchers tested the therapy in mouse models of type 1 and 2 diabetes.. The signs of the disease quickly reversed, and stayed that way even a month after stopping the treatment.
The results are intriguing, but of course being an animal study means there's still much more work to be done before it could find clinical use. So far, harmine alone has recently undergone a phase 1 clinical trial in humans to test its safety and tolerability, while other DYRK1A inhibitors are planned for trials in humans next year. https://newatlas.com/medical/diabetes-reversing-drug-boosts-insulin-producing-cells/ XX Stem cell–derived beta-cell replacement therapy continues to show benefit in people with type 1 diabetes at a high risk for severe hypoglycemia. New info from Vertex shows that of a total 17 patients who received a full dose of their investigational allogeneic stem cell–derived, fully differentiated pancreatic islet cell replacement therapy (VX-880), three, thus far, have achieved the primary study efficacy endpoint of elimination of severe hypoglycemic episodes with A1c < 7% at 1 year and the secondary endpoint of insulin independence. Others are on the same trajectory, Piotr Witkowski, MD, PhD, professor of surgery at The University of Chicago, Chicago, said at the recent American Diabetes Association (ADA) 84th Scientific Sessions. In his presentation, Witkowski also provided details about the deaths of two study participants that the company had announced in January 2024, neither of which were related to the VX-880 product. In fact, there have been no severe adverse events related to the product itself, with most due to either the infusion procedure or the immunosuppression. "These data highlight the curative potential of VX-880 in people living with type 1 diabetes and support further evaluation of VX-880 toward pivotal development," Witkowski said. For now, patients selected for the study are those who experience frequent severe hypoglycemia deemed to be a greater risk to the patient than that of immunosuppression. However, Ahn pointed out, "With VX-880, the obvious fly in the ointment is the need for immunosuppression which carries significant risk…There are multiple solutions being proposed, but we are still waiting for data as promising as the initial Vertex data is on that front." https://www.medscape.com/viewarticle/stem-cell-derived-islets-continue-show-benefit-t1d-2024a1000cx1 XX Still lots of COVID studies coming in about type 1. A German study suggests COVID 19 may speed up progression of existing but presymptomatic T1D in kids. These researchers had been screening and following children in an early presymptomatic stage of type 1 diabetes for several years. They noticed an increase in the numbers of Incidence of clinical type 1 diabetes nearly doubled after the pandemic started. "We know that the virus can infect the pancreatic islets so it could be causing damage or change in the beta cells that make insulin," said Ziegler when discussing possible mechanisms behind this association. "Second, there is generalized inflammation during the infection and there may be a stimulation of the immune response. Third, there could be metabolic stress from the infection that affects the beta cells that make insulin. To dive into this topic, youth were identified in the German Fr1da-screening program from 2015 to 2023. All patients had presymptomatic diabetes defined as persistent, confirmed positive results for two or more islet autoantibodies. Their progression was monitored at 3- to 6-month intervals. Clinical type 1 diabetes was defined according to American Diabetes Association
COVID infection was either self-reported via the family or identified with SARS-CoV-2 antibodies were confirmed in blood samples collected at study visits.
Vaccination against COVID-19 may be one way to protect presymptomatic type 1 diabetes youth from progression, Ziegler added. She said her group is currently testing whether COVID-19 vaccination can reduce new-onset, presymptomatic type 1 diabetes in a clinical trial of children with genetic risk factors for the condition. https://www.medpagetoday.com/endocrinology/type1diabetes/111084 XX The FDA says no – for now - to Novo Nordisk's weekly insulin. This has been approved in Canada and should be available there shortly. But the FDA says it wants more information related to the manufacturing process and the type 1 diabetes indication to complete the review. Novo said it does not expect to be able to fulfil the requests this year, and that it will work closely with the FDA regarding the next steps. The regulator's decision follows its outside panel's vote against the use of the weekly insulin icodec, in patients with type 1 diabetes due to risks of low blood sugar. XX A couple of weeks ago we spoke to the attorneys taking on CGM monitronig in schools. They've helped a family in Connecticut and set a precdent. A child with autism and diabetes was not getting reasonable accommodations under the federal Americans with Disabilities Act in a public preschool program. I'll link up the press release from the DOJ but this family wasn't getting any support and it just wasn't safe. The lawyers here tell me the ruling and settlement is just going to help them going forward as they try to make schools complient with CGM as a reasonable accomodatin. https://www.justice.gov/usao-ct/pr/aba-therapy-provider-make-changes-comply-americans-disabilities-act
XX Ozempic could lower the risk of dementia and a range of other mental problems compared with other existing treatments for patients with diabetes. What's more, researchers found that Ozempic cut nicotine dependence in those patients.
This study relied on medical records from more than 100,000 U.S. diabetes patients, including more than 20,000 who were prescribed semaglutide between December 2017 and May 2021. After a year, patients who took Ozempic had a 48% lower risk of developing dementia than those on Januvia. The risk in Ozempic patients was also 37% lower than those who took Glucotrol and 9% lower than those on Jardiance. Notably, previous research has determined that diabetes patients are at a greater risk of developing dementia. But the authors emphasized that the analysis is observational. The results need to be replicated in a controlled trial that assigns patients to randomly take Ozempic and the other drugs, according to Dr. Max Taquet, another Oxford clinical lecturer and senior study author. https://www.cnbc.com/2024/07/16/healthy-returns-ozempic-may-lower-dementia-risk-nicotine-use.html XX
Edgepark Commercial XX The Omnipod 5 with Dexcom G7 integration is now available through select pharmacies with full availability expected in the fall.
The System uses new Pods that are compatible with both Dexcom G6 and G7, but the prescription code will stay the same as the current Omnipod 5 Pods. This means the community will have similar insurance coverage and access to what they have with Omnipod 5 today.
If you're looking to start on Omnipod 5 and you're currently using Dexcom G7, your doctor will need to send a prescription for both the Omnipod 5 Intro Kit and Omnipod 5 Pods, compatible with Dexcom G6-G7, to ASPN Pharmacies.
You can learn more at https://www.omnipod.com/innovation/dexcom-g7.
If you are already using Omnipod 5, you will get the new Pods compatible with Dexcom G6 and G7 through your Pod refills. You do not need a new prescription. The week of July 29th, you will receive a free software update for the Omnipod 5 App to your Controller or compatible Android smartphone which is needed to use the System with Dexcom G7. Accept the update. We recommend you continue to use your current Omnipod 5 Pods and Dexcom G6 supplies until the new Pods compatible with Omnipod 5 with Dexcom G6-G7 are available at your preferred pharmacy.
We'll email our users when the new Pods are available in most pharmacies.
You can learn more at https://www.omnipod.com/innovation/new-compatible-devices
XX Big promises about long-term implantable blood glucose monitor from a company called Focus. They say they're partnering with Glucotrack to quote - transform how people with diabetes interact with their condition. They're not calling this a CGM – rather it's a CBGM, continuous blood glucose monitor because it will measure glucose levels in blood, not in interstital fluid like CGMs do. They company says this is a fully subdermal location, with no external wearable. In preclinical studies, the CBGM has a MARD of 4.7% at day 90. That is MUCH lower than CGMs on the market – Dexcom and Libre are in the low 8s right now. BUT.. it hasn't been fully tested in people yet. Human clinical trials are set to start later this year. https://www.drugdeliverybusiness.com/focus-collaborates-glucotrack-implantable-cbgm/ XX Big congrats to Jamie Ferrer (Chy-may Fer-rare) On Monday, Ferrer's dream was realized when the Twins selected the Florida State outfielder in the fourth round (No. 126 overall) during Day 2 of the MLB Draft. Minnesota vice president of amateur scouting Sean Johnson said the club had its eyes on Ferrer since high school. "Recently, I was in Orlando at a conference called, "Friends for Life with CWD [Children with Diabetes]," and we had an event that was a sports day. … Kids would come up to me and either them or their families would ask me how I dealt with this [or that]," Ferrer said. "And seeing their faces light up whenever I said I was diagnosed at three and I played college baseball. … You hear people tell you no and that you can't do this because you have Type 1 diabetes … So why not inspire as many people as I can?"
"I'm super proud of being a Type 1 athlete, and it's something that I'll never shy away from talking about or showing off my insulin pump because it's who I am and it's something that I've had to deal with my entire life." https://www.mlb.com/news/jaime-ferrer-selected-no-126-overall-by-twins-in-2024-mlb-draft XX Join us again soon! | |||
| Snap a photo, know your carb count: The story behind Snaq with founder Aurelian Briner | 04 Nov 2025 | 00:32:25 | |
Taking a photo of your food and getting an accurate carb count seemed like a pipe dream just a few years ago, but this week's guest says it's here. Snaq wants to help you get nutritional info, and then see how that food actually affects blood glucose, thanks to integrations with CGMs, insulin pumps, and activity trackers. Snaq founder Aurelian Briner explains how his wife's type 1 diagnosis inspired the company, how it all works (and who owns the data), and what's next. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections. | |||
| Navigating the insurance maze with T1D - consultant (and D-Mom) Emily Adams | 16 Jul 2024 | 00:45:16 | |
This week, I think it's fair to say that we all struggle with insurance issues. Diabetes – or any chronic condition – increases the hoops we jump through, the expense and the stress. I'm talking to Emily Adams an employee benefits consultant to get some advice about how to navigate. Emily thought she knew the system pretty well, but then her daughter was diagnosed with type 1 and she learned on a personal level how complex our system is. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out - registration is open for Denver and Philadelphia! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections. | |||
| My son was diagnosed with T1D at age two. How was his first year away at college? | 09 Jul 2024 | 00:41:38 | |
When my son was diagnosed with type 1 more than 17 years ago, the day he'd leave home seemed very far away, but also something we knew we needed to plan for. Well, Benny finished his Freshman year of college – he goes to school 300 miles away – and he's here to talk about it. We answer your questions about how it went, how he managed, how I managed and what's next. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Previous episodes with Benny Previous episodes with Lea Find out more about Moms' Night Out - registration is open for Denver and Philadelphia! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections. | |||
| In the News... Generic GLP-1, All-in-one sensor and infusion set, 365-day CGM, T1D & Roblox and more! | 05 Jul 2024 | 00:09:02 | |
It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: The Eversense CGM could soon be approved for one year of continuous use, the first generic GLP-1 medication is launched, a new company tauts and all-in-one sensor and pump infusion set, a new diabetes accessory in the Roblox game, and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX The first ever generic GLP-1 medication will soon be available in the US. It's a generic of Victoza, originally approved by the FDA in 2010 for diabetes, is part of the same class of drugs that includes Ozempic and Mounjaro. Liraglutide is Glucagon-like peptide-1 receptor agonists (otherwise known as GLP-1s or GLP-1 RAs) are a class of incretin drugs that mimic the body's natural hormones to help treat diabetes and obesity. However, the popularity of the drugs has spiraled out of control at times, leading to shortages and supply chain issues in the US and abroad. The arrival of a GLP-1 generic drug provides reasons to be hopeful for doctors and patients alike, but there are also caveats. Couple of caveats - liraglutide is injected once daily (vs. weekly) and many doctors say it doesn't work as well for as many people as semaglutide and terzepatide. No confirmation on the price Two other generic options are being developed and could launch in December 2024. Patents for newer GLP-1 medications like Ozempic and Wegovy won't expire until several years down the road https://www.healthline.com/health-news/victoza-generic-glp1-drug-available XX Senseonics plans to launch a 365-day sensor in the U.S. in the fourth quarter of this year. A one-year Eversense CGM could be a game changer for the company.
In 2024, Senseonics expects to more than double U.S. new patient starts and increase the global installed base by around 50%. The growth is built on the current 180-day version of Senseonics' implantable Eversense CGM. Eversense's 180-day sensor can need calibrating twice a day, something Senseonics CEO Tim Goodnow said "has been a competitive disadvantage." Users calibrate the 365-day sensor once a week. Senseonics is in talks with insulin pump manufacturers about integrating its Eversense CGM with their devices but has yet to commit to a timeline for finalizing an agreement. https://www.medtechdive.com/news/senseonics-365-day-cgm-2025-sales/719717/ XX People who take Ozempic or Wegovy may have a higher risk of developing a rare form of blindness, a new study suggests. Still, doctors say it shouldn't deter patients from using the medicines to treat diabetes or obesity.
Last summer, doctors at Mass Eye and Ear noticed an unusually high number of patients with non-arteritic anterior ischemic optic neuropathy, or NAION, a type of eye stroke that causes sudden, painless vision loss in one eye.
The condition is relatively rare — up to 10 out of 100,000 people in the general population may experience it — but the doctors noted three cases in one week, and each of those patients was taking semaglutide medications. The risk was found to be greatest within the first year of receiving a prescription for semaglutide.
The study, published Wednesday in the medical journal JAMA Ophthalmology, cannot prove that semaglutide medications cause NAION. And the small number of patients — an average of about 100 cases were identified each year — from one specialized medical center may not apply to a broader population. The ways that semaglutides interact with the eyes are not entirely understood. And the exact cause of NAION is not known either. The condition causes damage to the optic nerve, but there is often no warning before vision loss.
For now, patients who are taking semaglutide or considering treatment should discuss the risks and benefits with their doctors, especially those who have other known optic nerve problems such as glaucoma or preexisting visual loss, experts say https://www.reuters.com/business/healthcare-pharmaceuticals/wegovy-ozempic-linked-with-sight-threatening-eye-disorder-study-2024-07-03/ XX We got some updates at ADA about the over the counter CGMS Dexcom Stelo and Abbot's Libre. Dexom plans a late august launch of stelo, which you'll order from their website – it won't be physically in stores. Abbott also plans to sell its wellness-oriented Lingo device this summer through an e-commerce website. That's a sensor that's been available in other coutnires for a while, but was recently okayed in the US. It's not meant for people with diabetes. The Libre Rio is designed or adulst with type 2 who don't use insulin. No timing yet on that product's launch. Neither Abbott nor Dexcom have disclosed pricing for the upcoming products. https://www.medtechdive.com/news/abbott-dexcom-over-the-counter-cgm-launch/719928/ XX Insulet is looking to expand the label for its Omnipod 5 insulin pump for people with Type 2 diabetes. The company said Friday it recently filed with the Food and Drug Administration. Insulet presented study results at the American Diabetes Association's 84th Scientific Sessions that evaluated Omnipod 5 in people with Type 2 diabetes who were taking basal insulin or multiple daily injections. The results showed "substantial improvements in blood glucose outcomes and overall quality of life," said study chair Francisco Pasquel, an associate professor of endocrinology at Emory School of Medicine. Omnipod 5 is currently cleared in the U.S. for people with Type 1 diabetes. Insulet hopes to expand the pump to people with Type 2 diabetes, with an expected launch in early 2025. The FDA has not yet cleared any automated insulin delivery systems for people with Type 2 diabetes, Insulet said. The company has a basal-only insulin pump, called Omnipod Go, that was cleared for people with Type 2 diabetes last year, but it does not connect to other devices. Even though Omnipod 5 is not currently indicated for Type 2 diabetes, doctors prescribe it for their patients with full reimbursement since the pharmacy channel doesn't distinguish between Type 1 or Type 2 patients, J.P. Morgan analyst Robbie Marcus wrote in a research note on Sunday. https://www.medtechdive.com/news/insulet-omnipod-5-type-2-diabetes-study/719644/ XX In the keynote address at the American Diabetes Association annual conference, FDA Commissioner Dr. Robert Califf expressed concerns about the rising rates of diabetes in the U.S. Though revolutionary medications and technologies for diabetes and weight loss continue to emerge, these treatments are vastly underused. The silver lining lies with type 1 diabetes therapies, which are showing great promise in clinical trials. "For the larger epidemic of type 2 diabetes, we're failing right now," Califf said. "I don't say that lightly." A huge problem, Califf said, is access. While most health insurance plans cover medical devices and medications for diabetes, without insurance, costs add up quickly. Ozempic, for example, costs nearly $1,000 per month without insurance. Studies have found that regardless of insurance status, roughly 26% of Americans skipped or delayed treatment due to cost. https://diatribe.org/diabetes-management/fda-commissioner-says-were-failing-people-type-2-diabetes XX Embecta presented two abstracts at the American Diabetes Association Scientific Sessions last weekend making the case for its insulin patch pump for Type 2 diabetes. The company submitted the device for Food and Drug Administration clearance in late 2023. The diabetes device company developed a patch pump with a larger insulin reservoir that can hold up to 300 units. Embecta, which is better known for making equipment such as pen needles and insulin syringes, has been developing its first patch pump. The company found that a device with a larger insulin reservoir could provide longer wear times and fewer disposable patches. https://www.medtechdive.com/news/embecta-insulin-patch-pump-volume-american-diabetes-association/719779/ XX
Pump/CGM sensor in one The niaa signature patch pump, shown with a watch displaying current blood sugar level The niaa signature patch pump has a manual bolus button and is part of an in-development AID system. Swiss technology maker Pharmasens demonstrated a new semi-reusable tubeless patch pump and glucose sensor in the same compact device, called the niia signature, which the company says can be worn for five days.
The top of the device, which includes Bluetooth connectivity and the electronic and mechanical parts to control the pump, separates from the disposable 300-unit reservoir along with the adhesive used to attach the device to the body via a steel cannula. A small button on the device allows manual bolusing. The company says an AID system will manage the device, controlled by smartphone.
PharmaSens' simpler basal-bolus patch pump, the niia essential, was submitted for FDA approval in late December. Availability of the niia signature AID system has yet to be announced. https://diatribe.org/diabetes-technology/diabetes-technology-display-ada-2024 XX Edgepark Commercial XX New international consensus statement offers guidance on the care and monitoring of people who are at high risk for type 1 diabetes (T1D). This is all about screening and testing for islet autoantibodies. These individuals are classified as: At risk or Stage 0 (single autoantibody or transient single autoantibody), Stage 1 (two or more autoantibodies with normoglycemia), and Stage 2 (two or more autoantibodies with dysglycemia but without symptoms and not yet meeting diagnostic criteria for Stage 3 clinical T1D). The document was presented on June 24, 2024 in a 90-minute symposium at the American Diabetes Association's annual Scientific Sessions and published simultaneously in both Diabetes Care and Diabetologia. "This is not guidance around who to screen or when to screen. This is guidance for the hundreds of thousands of people around the world who have participated in screening, mostly through research programs, and have been identified with positive autoantibodies and need care in the clinical setting," panel co-chair Anastasia Albanese-O'Neill, PhD, APRN, CDCES, of Breakthrough T1D, told Medscape Medical News.
The recommendations also include when to start insulin, and how to provide education and psychosocial support to individuals and family members of those given the early-stage T1D diagnosis. https://www.medscape.com/viewarticle/experts-advise-early-risk-monitoring-type-1-diabetes-2024a1000bpo XX Roblox has added a diabetic option, complete with insuli pen and Dexcom You can find it in the marketplace JDRF – now breakthrough t1d – started a world in roblox a couple of years ago as well Roblox is a super popular online game that a lot of kids play. https://www.roblox.com/games/5823990610/Breakthrough-T1D-World XX FFL next week! Join us again soon! | |||
| Dexcom updates from ADA 2024 with CEO Kevin Sayer | 02 Jul 2024 | 00:36:33 | |
Stacey sits down with Dexcom's CEO for an in-person interview at ADA Scientific Sessions. Dexcom made a little bit of news at the conference, but it's a less-trumpeted replacement policy that had you all asking a lot of questions. We'll go through the latest news, updates, sensor issues, and a peek into the future with Dexcom's CEO Kevin Sayer. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out - registration is open for Denver and Philadelphia! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com | |||
| What is EPI? DIY diabetes pioneer Dana Lewis wants you to know your risk | 25 Jun 2024 | 00:42:20 | |
DIY Pioneer Dana Lewis was diagnosed with something called EPI – exocrine pancreatic insufficiency a couple of years ago. She'd never heard of it and was shocked to find out diabetes is considered a common co-condition. In fact, 20-30 percent of people with diabetes can end up with EPI. EPI can cause a lot of discomfort and stomach issues – and health issues if left untreated. Of course, Dana jumped in, publishing a review of studies and now- creating studies of her own. She'll explain what she's doing, why she needs your help, and more about this condition that doesn't get much attention. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find your Exocrine Pancreatic Insufficiency Symptom Score using Dana Lewis's new tool: https://danamlewis.github.io/EPI-PEI-SS/ Learn more from Dana here Find out more about Moms' Night Out - registration is open for Denver and Philadelphia! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com | |||
| In the news.. Insulin pen shortage, Omnipod 5 update, once-weekly insulin approved in Canada, and more! | 21 Jun 2024 | 00:07:59 | |
It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: South Africa runs out of insulin pens - and why this could happen anywhere, once-weekly insulin is approved in Canada, update on Omnipod 5 with Dexcom G7 rollout, more older people are getting type 1 but more people are living longer with it, CGM at the Olympcs and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:
Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX Quick note – the American Diabetes Association Scientific Sessions is this weekend. That means new research studies will be released, technology announced, and likely lots of news will be made. I'm recording this before the conference starts – if there's enough going on we may have an additional In the News next week. XX Our top story right now… XX No more insulin pens for South Africa.. .as the pharmaceutical industry shifts production priorities to blockbuster weight-loss drugs. Novo Nordisk, the company that has supplied South Africa with human insulin in pens for a decade, opted not to renew its contract, which expired last month. No other company has bid on the contract — to supply 14 million pens for the next three years, at about $2 per pen. Novo Nordisk's drugs Ozempic and Wegovy, which are widely prescribed in the U.S. for weight loss, are sold in single-use pens produced by many of the same contracted manufacturers who make the multidose insulin pens. A month's supply of Ozempic in the United States costs about $1,000, far more than insulin. Novo Nordisk dominates the global market for insulin in pens and has supplied South Africa since 2014. Eli Lilly, the other major producer, has indicated in recent months that it is struggling to keep up with the significant demand for its weight-loss drug Zepbound. Novo Nordisk is continuing to supply human insulin in vials to South Africa, where more than four million people live with diabetes, but pens are considered much easier to use and more precise. The vial system was phased out for most South Africans in 2014. But recently, South Africa's National Department of Health instructed clinicians that they should teach patients how to use vials and syringes of insulin instead of pens. I posted about this already and said this is a canary in the coal mine and everyone going to ADA should be asking Novo and Lilly about this. GLP medications are fantastic but insulin cannot be left behind. https://www.nytimes.com/2024/06/19/health/insulin-pens-south-africa-ozempic-wegovy.html XX Once a week basal insulin – for type 1 and type 2 – comes to Canada. Novo Nordisk announced that it's version of insulin icodec will be available starting June 30th. They are calling it.. Awiqli – I promise I didn't make that up. Canada is the first country to get the product. Awiqli works as a time release of insulin over the course of a week. It is more expensive. And Canada's Drug Agency, which assesses drugs and recommends whether they should qualify for reimbursement under public drug plans, is still doing the math here. No word on private insurers coverage yet. An FDA advisory board recently passed on approving weekly basal for people with type 1, saying the risk of low blood sugar was too great. But the full FDA hasn't yet weighed in.
https://www.ctvnews.ca/health/world-s-first-weekly-insulin-injection-coming-to-canada-in-2-weeks-manufacturer-says-1.6929321 XX The prevalence of people over 65 living with type 1 diabetes went up 180% in the past 30 years, a new study finds. That's an increase of 1.3 million people over 65 in 1990 with the disease to 3.7 million in 2019, the authors noted in a study published on June 12 in The BMJ. Data included people from 204 countries and territories from 1990 to 2019. Dying from type 1 diabetes slipped by about 1% every year since 1990, the data also showed. The mortality for people 65 and up went down by 25% during the three decades covered in the study. The most rapid prevalence was in North Africa and the Middle East, and Western Europe, and the slowest increase in prevalence was in North America. All 21 regions around the world had an increased prevalence of type 1 diabetes in people over 65. The disease no longer contributes to a reduced life expectancy for many people due to medical care improvements, say these researchers. https://www.mcknights.com/news/report-type-1-diabetes-prevalence-in-older-adults-nearly-triples-since-1990s/ XX Hearing more about the limited rollout of Omnipod 5 with the Dexcom G7. This was announced in February but just seems to really be getting underway. A few people have received emails that people new to the system will be getting this first.. but that at the end of July current users will get a controller update so they can use G7 with the current pods. We'll have more on this soon – I don't have a link for you - but thanks to all of you who sent me those emails very much appreciate it. XX New life possible for Korean insulin pump EOPatch– this is a competitor to the Omnipod. A court has killed an injunction that meant the company, EOFlow, could not bring the patch pump to the US. Last year, the court initially granted that injunction and Medtronic backed out of an acquisition plan. No word yet from Medtronic if that deal is back on.. or if another company may work to bring EOFlow to the US. https://news.bloomberglaw.com/business-and-practice/ban-against-insulin-pump-patch-sales-reversed-by-federal-circuit XX The CeQur Simplicity patch is now FDA-cleared for up to 4 days of wear. This is a mechanical patch pump that replaces fast-acting injections. This is an extension from 3 days to four.. now each patch replaces up to 12 injections making it the longest wearable insulin delivery patch. The company says that can be 1000 fewer shots a year. Marketed mostly to people with type 2 diabetes who use insulin, the company says nearly 90% of patients using CeQur Simplicity reported following their insulin regimen better as compared to multiple daily injections.(4) The patch is clinically proven to improve glycemic control, with patients achieving significantly improved A1C and time-in-range (TIR) goals.(5,6) https://www.prweb.com/releases/cequr-simplicity-a-wearable-mealtime-insulin-delivery-device-obtains-fda-clearance-for-4-days-of-wear-to-further-simplify-diabetes-management-302173938.html XX A warning from Roche which says "dangerous counterfeits" of its diabetes medical devices ended up for sale on Amazon. Roche accused manufacturers and sellers based in India of selling counterfeit versions of test strips for its Accu-Chek glucometers. This is part of a federal lawsuit. Roche said the counterfeit test strips are expired or nearly expired products that are repackaged with counterfeit labels bearing Roche's registered U.S. trademarks and fake expiration dates. After the suit was filed, a judge granted Roche's request for a temporary restraining order to stop the defendants from selling the counterfeit products. The Amazon stores that were offering the products for sale appear to have been taken down. Amazon is not a defendant in the case, but Roche claims that as part of the alleged scheme all of the counterfeit products sent to the U.S. were stored at Amazon warehouses across the country, including in Brooklyn. https://www.cnbc.com/2024/06/10/roche-counterfeit-diabetes-medical-devices.html XX Edgepark Commercial XX Summer Olympics this year may be a showcase for CGMs. Abbott is sponsoring a Dutch long distance running, he'll be wearing the Libre. Other athletes are using the CGMs in training and may wear as allowed in their sports. There isn't a lot of proof yet that these devices make a big difference for people without diabetes.. but high level athletes are looking for any edge possible. Expect to hear a lot more about this in the lead up to the Olympics July 26th. https://learningenglish.voanews.com/a/olympic-athletes-turn-to-diabetes-technology-in-medal-chase/7653234.html XX Join us again soon! | |||
| The business of diabetes - Scott Strumello's perspective after 50 years of T1D | 18 Jun 2024 | 00:41:00 | |
Scott Strumello has lived almost 50 years with type 1. Diagnosed as a child in the 70s, he found the online community and started blogging. Scott has a unique perspective – with a background in finance and consulting, he's a reliable source of what's happening in earnings calls, legislation, and the business of diabetes. We have a great talk about what's coming in terms of biosimilars, the role of PBMs and some legal action that may happen this year. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Stacey's webinar with Breakthrough T1D Mountain West Chapter The Breakthrough T1D announcement video Find out more about Moms' Night Out - registration is open for Denver and Philadelphia! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com | |||
| JDRF is now "Breakthrough T1D" - Behind the rebrand (and other changes) | 11 Jun 2024 | 00:34:03 | |
JDRF… is no more. A rebranding and name change means the organization founded in 1970 by concerned parents will now be known as Breakthrough T1D. You can guess some of the reasons for this change – the "J" for juvenile has long been a turn off for adults living with type 1 – but some of the other reasons are surprising. We'll do a deep dive into what this means for the community, the fund raising and research, and the organization itself. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Stacey's webinar with Breakthrough T1D Mountain West Chapter The Breakthrough T1D announcement video Find out more about Moms' Night Out - registration is open for Denver and Philadelphia! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com | |||
| In the News... Dexcom to Apple Watch, Metformin during pregnancy, Mounjaro shortage update... and more! | 07 Jun 2024 | 00:10:31 | |
It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: Dexcom goes Direct to Watch in the US, Abbott gets FDA okay for its OTC CGM, new study about metformin during pregnancy, an update on semaglutides, JDRF changes its name, and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:
Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX Our top story this week – some CGM news… Dexcom announces Direct to Watch is here in the US. From the release: Using its own dedicated Bluetooth connection, Dexcom G7 sends glucose information and personalized alerts right to a user's Apple Watch. Dexcom G7 is the only CGM system that can display glucose on multiple devices simultaneously and independently, including on a smartphone, smart watch, receiver or connected automated insulin delivery system.‡ Apple products are built with strong privacy protections and users have control over their data in the Health app. (If you like to keep track of these things, we are just over 7 years since the official announcement this was going to happen) XX FDA approves Abbot's over-the-counter continuous glucose monitoring system. It's called Lingo and comes a couple of months after Dexcom won clearance for its Stelo over-the-counter CGM. Abbott has been selling Lingo in the UK as more of a lifestyle device – not aimed at people with diabetes. They call it a consumer biowearable designed to help people make decisions about their overall health and wellness; Lingo is not intended for use in diagnosis, treatment or management of a disease or medical condition. No word yet on exactly what kind of app they'll launch here in the US or if it will be marketed toward people with diabetes like the Libre currently is.. just as an OTC option. While it seems like the same hardware, the company has not confirmed that. https://www.drugdeliverybusiness.com/abbott-wins-fda-clearance-for-its-lingo-otc-glucose-monitor/ XX New study looking at the use of continuous glucose monitors (CGMs by rural children and adolescents living with type 1 diabetes. Previous studies examining the use of CGMs by children relied on prescription records to identify use of these devices, but just because someone is prescribed a CGM does not mean that they use one; barriers such as cost can stand in the way. this study instead identified use of these devices according to billing codes for the interpretation of CGM readings by the provider. The results unearthed a sizeable disparity. Those living in rural areas were significantly less likely to use a CGM than those in urban areas, even after adjusting for sex, race or ethnicity and insurance type. Specifically, compared with youth living in urban areas, the use of CGMs was 31% lower for children and adolescents living in small rural towns, and 49% lower for those living in isolated rural towns. The gap between rural and urban patients persisted across the four years of the study, even as the use of CGMs increased for all patient types during this time. These results are also relevant to people with type 2 diabetes who require insulin, Tilden said. The results also revealed that non-White patients, those who had public insurance and patients who lived in areas with a higher NPI all were less likely to use CGMs. More research is needed to explore the reasons for these disparities, but Tilden said they likely are a function of such issues as cost, reduced internet access, which CGMs require to relay their data, and distance from clinics and Medicaid-contracted pharmacies.
The next step is figuring out how to eliminate those disparities. These researchers are seeking funding to design an intervention that uses telemedicine and partners with a network of 35 clinics across Kansas to deliver specialty care to diabetes patients in rural areas.
https://www.kumc.edu/about/news/news-archive/diabetes-monitoring-disparities.html XX Metformin is just as safe to use during pregnancy to treat type 2 diabetes as insulin. The study, which hasn't been published yet in a peer-reviewed journal, tracked health data and potential long-term side effects of using metformin during pregnancy for up to 11 years postpartum. While today's popular GLP-1 medications, such as Ozempic, are not approved yet for use during pregnancy, metformin and insulin have been used during pregnancy for decades. https://www.medicalnewstoday.com/articles/metformin-may-be-as-safe-as-insulin-to-treat-diabetes-during-pregnancy XX Once weekly basal insulin is a no go from an FDA advisory panel. They found the potential benefits of the investigational once-weekly basal insulin analog icodec (Novo Nordisk) don't outweigh the increased risk for hypoglycemia in people with type 1 diabetes. We've been following this for a long time. Most of the trials here have been in people with type 2 – and the FDA hasn't publicly raised concerns about efficacy and safety seen in any of those trials. But the type 1 trial found a significant increase in serious or severe hypoglycemia with icodec compared with degludec (4.66 vs 1.0 events per 100 patient-years; 14 events in nine patients versus three in three patients), with the greatest incidence in the icodec group on days 2-4 after injection. None of the events resulted in treatment discontinuation or study withdrawal. This doesn't mean the FDA can't approve the drug – and the panel mentioned that they hope the FDA would work with Novo Nordisk to – quote - make sure that if this is approved there are as many guardrails as possible to make sure we don't harm people with type 1 diabetes." https://www.medscape.com/viewarticle/advisory-panel-votes-against-once-weekly-insulin-type-1-2024a10009we XX The shortage of Ozempic and Mounjaro continues… with some doctors offering advice of what to do if you can't fill your prescription. Health care company Ro recently launched a public crowd-sourced shortage tracker to help patients. The company says they also share the patient-reported shortages to the FDA. Chae says some patients could discuss with their doctor off-label use of other medications, like liraglutide injections (such as Trulicity, for example), depending on their preexisting conditions. Patients may also consider trying compounded semaglutide. Compounded drugs are made to order in local pharmacies, but Chae says be wary of them: Because of their bespoke nature, the drugs' safety isn't regulated by the FDA. "The state of Mississippi, North Carolina and West Virginia have banned these compounded drugs," he said. https://www.scrippsnews.com/health/popular-diet-and-diabetes-drugs-in-short-supply-as-demand-surges XX Commercial XX Big news from JDRF – they've changed their name to "Breakthrough T1D." Here's the statement: "Breakthrough T1D was selected following a rigorous, data-informed process because it more accurately conveys the nonprofit's ability to connect with and work on behalf of the entire type 1 diabetes community," The median age for a person living with T1D worldwide is 37 years. Only about one in five are aged 20 years or younger, two thirds are aged 20-64 years, and another one in five are aged 65 years or older.
The organization was founded in 1970 by parents of children with T1D and was originally called the "Juvenile Diabetes Foundation." The "research" part was added in 2012 to reflect that aspect of its mission. We will have much more on this next week – Tuesday's episode is an interview with JDRF. Oops with Breakthrough T1D. XX Android users – heads up! The FDA has approved a hybrid, closed-loop, insulin-delivery Android app. In May, CamDiab, revealed that the CamAPS FX had received approval. CamAPS FX is approved for people with type 1 diabetes who are two years of age or older, including those who are pregnant.
CamAPS FX works in unison with the FreeStyle Libre 3 and the Dexcom G6 to produce a hybrid, closed-loop system that is compatible with the Ypsomed mylife YpsoPump. The app and those pumps are already approved in several other countries. You may recall that the YspoPump had a partnership with Lilly to bring that pump to the US – but that deal died in 2022. Yspomed is still moving forward to get FDA approval for their pump. https://beyondtype1.org/fda-approves-camaps-fx-hybrid-closed-loop-insulin-delivery-app/?fbclid=IwZXh0bgNhZW0CMTEAAR137RhLAt2GfIJ_BBYMrhU2R-maQ0EQmwOFhPfKN9iCnG2BKWY6dEB0sTk_aem_ATLPk1xWOnLNzPz7LvYINbTdCVMZk7pcRmma2pgG5MIo0OfinomTSgjsTsTpW_fE6GNVRnScZS6UGzaTvP1SewNW XX Driven by payments for diabetes treatments — especially insulin — prescription drugs for metabolic diseases now make up nearly one quarter of total national pharmaceutical spending, reported a study of spending trends by therapeutic class. The detailed examination of a decade's worth of US drug spending also found changes in who pays for the medicines, with an overall drop in out-of-pocket costs, except in the metabolic disease category. The findings add to concerns about the costs of US diabetes treatments. Annual US spending on diabetes medicines surged from $27.2 billion in 2011 to $89.2 billion in 2020, according to this paper was published online in Research in Social and Administrative Pharmacy. In the same period, total annual pharmaceutical spending rose at a far slower rate. Yet much of the persistent gain in the cost of diabetes treatments in this same period was due to a decades-old drug, insulin, a cornerstone of diabetes care. https://www.medscape.com/viewarticle/study-raises-concerns-about-rising-cost-diabetes-meds-2024a1000a8e XX The number of people aged over 16 with insulin-dependent diabetes and eating disorder symptoms is as high as one in four, a study has revealed. Researchers from the University of Eastern Finland examined the findings from 45 past studies, looking at data from almost 11,600 people with insulin-dependent diabetes. They say that understanding the extent of the issue is the first step in developing treatment pathways, citing Finland as an example of a country which does not have care pathways for people with both diabetes and eating disorders. Of course, neither does the US. Typical eating disorder symptoms include restricting food intake and binge eating. Symptoms particular to insulin-dependent diabetes include insulin omission, which is when individuals restrict or skip insulin doses due to fears of putting on weight. The prevalence of eating disorder symptoms was higher in women than in men, a finding previously made in young people too. The age of an individual was not found to be a factor, with eating disorders occurring regardless of age group. https://www.diabetes.co.uk/news/2024/jun/1-in-4-people-with-insulin-dependent-diabetes-have-eating-disorder-symptoms-research-shows.html XX Congrats to Kate Farnsworth who recently won Diabetes Action Canada Catalyst for Change award. Many of you know Kate from the early DIY days.. Kate Farnsworth is the patient partner co-lead for the Innovations in Type-1 Diabetes Program. Kate has been heavily involved in the Do-It-Yourself #wearenotwaiting movement since her daughter Sydney was diagnosed with type 1 diabetes at the age of 8. With a background in information technology and graphic design, Kate has lent her skillset to developing diabetes watch faces for remote monitoring used by patients worldwide. Kate has created an online patient-driven support community for people who are exploring DIY closed-loop solutions and continues to advocate for all people with diabetes to have access to the best tools to manage their diabetes. Very nice to see this award go to someone very well deserved. XX Join us again soon! | |||
| How close are we to glucose-responsive insulin? An update from Sensulin's CEO | 04 Jun 2024 | 00:30:18 | |
We've been hearing about smart insulin for a long time. This refers to an insulin that would react to glucose levels and adjust by itself with no external device, like a CGM, needed. You'd inject and let the insulin do the work. I'm talking to Sensulin CEO Mike Moradi about where their version of this amazing sounding technology stands, his family connections that really feeds his passion here, and what has to happen to get glucose-responsive insulin into the hands of people who could benefit. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out - registration is open for Denver and Philadelphia! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com | |||
| What Extreme Adventures Can Teach Us About "Ordinary" Life with T1D, with Patrick Mertes | 28 Oct 2025 | 00:42:18 | |
What can those of us who will never climb the highest mountains, or take on extreme outdoor challenges – learn from those who do? Patrick Mertes and Michael Shelver have hiked and biked – and fallen – on incredible expeditions, while living with type 1. They'll share what they've learned, how those lessons apply to everyday life with type 1, what their family's think and what's next. Plus, Patrick talks about why diabetes camps remain such a cornerstone of confidence and connection, and how parents can help their kids face challenges that truly build independence. This is the keynote address from Moms' Night Out Minneapolis. Make sure to join us in 2026 for this amazing event! More info: at the Moms' Night Out main page This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Learn more about Project 50 in 50 Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections. | |||
| Disney DAS pass changes, plus GlucosePath & Catalyst studies | 28 May 2024 | 00:38:27 | |
Disney very recently made some changes to their Disability Access Services program – often referred to as a DAS pass at Disney World and Disney Land. We're going to talk about why this happened, what it means for you, and what else is going on at Disney. Note: this interview was taped BEFORE the changes took place. More about Len Testa's Touring Plans here More about the DAS changes here We're also spending some time talking about a new service for doctors called Glucosepath and about a new surprising study about cortisol and diabetes. I'll also explain how these two guests can talk about all of these issues.. Len Testa is co host of the fabulous Disney Dish podcast and the creator of Touring Plans the app and service of The Unofficial Guides to Walt Disney World, Disneyland and Disney Cruise Line. Testa is all about the math of theme parks – his guides are there to maximize the magic as he says – to make your waits shorter and save money – and it's all based on calculations from his team. He teamed up with endocrinologist Dr. Bradly Eilerman to create GlucosePATH which uses computer science and clinical data to evaluate every possible treatment option, using data from the patient, FDA, and peer-reviewed journals, in just a few seconds. Dr. Eilerman also talks about the Catalyst study which looks at people with type 2 diabetes and measures cortisol. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out - registration is open for Denver! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com | |||
| Insulin and Glucagon in the same pump? Explaining the Beta Bionics - Xeris partnership | 21 May 2024 | 00:38:30 | |
This week, creating a bihormonal pump – using insulin and glucagon in one device - has been the goal of Beta Bionics since before the company even had that name. Now that they've launched the insulin-only version of their iLet, we're getting an update on the dual chambered version. The big news is a new agreement with Xeris to supply that shelf-stable glucagon. But there are still a lot of questions. We're talking to the CEOs of both companies. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out - registration is open for Denver! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com | |||
| Inside the class-action lawsuit against insulin pricing, with Attorney Steve Berman | 14 May 2024 | 00:26:45 | |
This week, talking with one of the lawyers bringing a class-action lawsuit against the insulin companies.. a lawsuit that has been inching forward since 2017. It was set to be settled for 500-million dollars and a four year price cap, but then judge said no. Attorney Steve Berman will talk about that last minute surprise, why he's still going forward, and what he needs now from the diabetes community. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. My guest is Attorney Steven Berman from the firm Hagens (Haagens like Haagen Daas) Berman. Steve co-founded Hagens Berman in 1993 after his prior firm refused a fast food e coli case. That turned out to be the famous case against Jack in the Box, which resulted in a class action settlement and changed many food safety laws. He's also been involved in cases against Big Tobacco and, as you'll hear, other medical pricing lawsuits. Learn more about the case and fill out the form to see if you're entitled to compensation here: https://www.hbsslaw.com/cases/insulin-overpricing#block-form-block-destination Find out more about Moms' Night Out - registration is open for Denver! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com | |||
| In the News.. T1D increasing in older adults, new iCGM designation, low BG prevention tested, and more! | 10 May 2024 | 00:07:48 | |
It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: more older adults are being diagnosed with type 1 and people with T1D are living longer, Eversense gets iCGM designation, new drug to prevent low BG is being tested, Tandem diabetes app recall, and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX Type 1 diabetes is increasingly affecting older adults in the US, with prevalence rates peaking in those aged 45 to 64, according to recent research published in JAMA.1 The life expectancy for people with T1D has increased over the last 15 years, which has led to increased prevalence among older adults.2 The CDC currently estimates that approximately 1.8 million people in the US have T1D.3 The study utilized data from the 2019 to 2022 cycles of the National Health Interview Survey (NHIS), representative of the noninstitutionalized US population. The study included over 141,000 participants (110,283 adults and 30,708 youths). The increasing prevalence of T1D in older adults suggests that further research is needed to develop treatment guidelines that include strategies to optimize treatment in older adults living with T1D. Current clinical practices often extrapolate from data on younger populations or those with type 2 diabetes, which may not be entirely appropriate for older adults with specific needs in terms of cardiovascular and glycemic management.
https://www.ajmc.com/view/t1d-prevalence-rising-among-us-adults-study-finds XX Pancreatic cancer research may have implications for diabetes. These reserachres were looking at an enzyme called focal adhesion kinase (FAK). During the trials, quote - "The pancreas looked weird, almost like it was trying to regenerate after an injury," Even weirder, a cluster of cells in the pancreas were expressing both insulin and amylase. In normal mice and humans, the blood sugar-regulating hormone insulin is produced by beta cells, while amylase, a digestive enzyme, is manufactured by different cells. The functions of acinar and beta-cells are very distinct, so it didn't make sense that the cluster of cells looked like a combination of the two. Esni and his team had in fact stumbled upon this holy grail. In a new Nature Communications paper, the researchers show that a FAK-inhibiting drug, which has been studied in cancer treatment, converted acinar cells into acinar-derived insulin-producing (ADIP) cells and helped regulate blood glucose in diabetic mice and a single non-human primate. The findings suggest that FAK inhibitors could be a new avenue as a replacement for insulin therapy in diabetic patients. With the eventual hope of launching a clinical trial to test FAK inhibitor in diabetes patients, Esni and his team are now planning long-term experiments in mice to look at the duration of hyperglycemia control after a single course of the drug in mouse models for type 1 or type 2 diabetes. They're also investigating the effects of FAK inhibition in pancreatic tissues from human donors. https://medicalxpress.com/news/2024-05-repurposed-cancer-drug-diabetes-nudging.html XX A report published today by Doctors Without Borders/Médecins Sans Frontières (MSF) and T1International shows astonishing markups by pharmaceutical corporations on insulin injection pens and newer diabetes medicines. Currently, only half of all the people in the world who need insulin have access to it. Doctors without borders is among the few humanitarian groups currently procuring insulin pens. Based on MSF's research of the cost of production, long-acting insulin pens, which are the standard of care in high-income countries, could be sold at profit for as low as $111 per patient per year, which includes insulin and the device needed to inject it. This is 30 percent less than human insulin in a vial with syringes, which have always been thought to be the most affordable option
The US must do more to ensure equitable access to diabetes drugs worldwide "While the announcement of a recent US Senate investigation into Novo Nordisk's GLP-1 drug prices is an important step, the US government must do more to ensure equitable access to diabetes drugs worldwide," https://www.doctorswithoutborders.org/latest/diabetes-only-half-people-who-need-insulin-world-have-access-it XX The U.S. FDA on Wednesday warned about a software glitch found in the Tandem Diabetes' t:slim X2 insulin pump, classifying the issue as a Class I recall, the agency's most serious type of recall. HOWEVER.. this happened in March and Tandem says it's been resolved. Here's what happened..
The error was found in the Apple iOS-based software version of the t:connect mobile app used for the t:slim X2 insulin pump with Control-IQ technology. The defect causes the app to crash down and relaunch repeatedly, leading to excessive Bluetooth communication, which in turn drains the pump battery and leads to an unexpected pump shutdown. More than 85K t:slim X2 insulin pumps distributed in the U.S. between February 12 and March 13 have been affected by the issue, which the FDA has categorized as a correction. Tandem Diabetes (TNDM) sent a letter to affected customers in March requesting them to update the app. After a discussion with the management, Citi said that 98% of users have updated their apps to version 2.7.1, released on March 13. The company has not seen any issues with the latest app version and expects the update to permanently fix the defect. Citi retains its Neutral rating on the stock. XX HIGH POINT, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced the submission of the study protocol to the FDA for the Company's first Phase 3 trial evaluating the safety and efficacy of its lead candidate, cadisegliatin, in adults diagnosed with T1D. The Phase 3 study will assess two doses of orally administered cadisegliatin versus placebo in patients currently being treated with multiple daily insulin injections and continuous subcutaneous insulin infusion, who use a continuous glucose monitor (CGM). The primary efficacy endpoint of the study will compare the incidence of Level 2 or Level 3 hypoglycemic events between cadisegliatin-treated subjects and those in the placebo group. It received a breakthrough therapy designation (BTD) based on its Phase II trial (NCT03335371), which showed a 40% decrease in the frequency of severe and symptomatic hypoglycaemic events along with a decrease in serum and urine ketone events in the treatment group. Cadisegliatin is not yet licensed or approved anywhere globally and has not been demonstrated to be safe or effective for any use. Cadisegliatin (TTP399) is an investigational liver-selective glucokinase activator that has been studied in healthy volunteers and in patients with type 1 and type 2 diabetes. XX Timing is everything.. the same day we released our episode about the Eversense CGM last week, Senseonics, in collaboration with Ascensia Diabetes Care, has announced that its Eversense product received an integrated continuous glucose monitoring (iCGM) designation from the US Food and Drug Administration (FDA). This marks Eversense as the first fully implantable device to achieve such status, paving the way for future devices of its kind through the FDA's De Novo pathway. The iCGM designation signifies that the system can be integrated with compatible medical devices, such as insulin pumps, to create an automated insulin delivery (AID) system. https://www.medicaldevice-network.com/news/senseonics-eversense-icgm-designation-fda/ XX Commercial XX
XX A big win for Georgians with Medicaid who have #diabetes. Governor Brian Kemp signed into law a bill that expands #CGM access to persons with Medicaid and diabetes who are insulin therapy and removes the age limitation and endocrinology requirement. Please see ADA press release below. Please share. https://lnkd.in/g_WVTNpi American Diabetes Association
XX 61-year-old ultrarunner Linda Carrier is the first woman to complete the World Marathon Challenge (seven marathons on seven continents in seven days) three times.
Plus, she has run 78 marathons and 55 half-marathons and is currently in the process of running a marathon in all 50 states with just 12 to go.
To add to the wow factor, Carrier has accomplished it all while managing type 1 diabetes for nearly 50 years.
"I naturally like to challenge myself, and when someone says [you have] a life-shortening disease, I'm like, heck it's not. I'm going to show them that I'll be the longest-living type 1 diabetic," Carrier told Healthline.
She was 14 years old when she learned she had the condition. Because her older sister had been diagnosed a few years before, Carrier was familiar with the symptoms. She also knew the outlook was daunting. She will finish her latest goal of running a marathon in all 50 states next October in Twin Cities, Minnesota. The race will be sponsored by Medtronic.
"Seems like the perfect way to finish," Carrier said. "And to show that type 1 diabetes should not stop you from reaching any of your goals, whatever it might be." https://www.healthline.com/health-news/linda-carrier-diabetes-marathon XX Join us again soon! | |||
| "You are raising fearless children" journalist Madison Carter speaks at Moms' Night Out Charlotte | 07 May 2024 | 00:58:04 | |
This week, what growing up with diabetes meant for career choices, financial decisions, and family relationships. Madison Carter is a local news anchor who makes T1D very visible – and she does not hold back. She's generous with incredible insight into how she was raised, sacrifices her family made and what her mom and dad have to say now. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out - registration is open for Denver! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com | |||
| "As active as I want to be" - Dianne Mattiace uses Eversense CGM to thrive with T1D in her 70s | 30 Apr 2024 | 00:43:03 | |
This week, managing type 1 diabetes into your 70s is a bit of uncharted waters.. While thankfully more and more people are living long with T1D, that wasn't always the case. I'm taking to Dianne Mattiace who is in her early 70s and was diagnosed as an adult, 30 years ago. She was the first person in the US to use the Eversense CGM when it was approved in 2018 and she's still using it today. She answers your questions about this implantable CGM, why she's stayed with it and what else she does to manage in retirement and beyond. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More about Eversense here Our previous episodes about Eversense here Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode Transcription: Stacey Simms 0:00 Dianne Mattisse 0:04 Stacey Simms 0:07 Dianne Mattisse 0:15 Stacey Simms 1:35 Dianne Mattisse 1:39 Stacey Simms 3:58 Dianne Mattisse 4:41 Stacey Simms 6:45 Dianne Mattisse 6:48 Stacey Simms 6:53 Dianne Mattisse 6:59 Stacey Simms 8:00 Dianne Mattisse 8:12 Stacey Simms 11:19 Dianne Mattisse 11:27 Stacey Simms 15:57 Dianne Mattisse 16:02 Stacey Simms 16:53 Dianne Mattisse 16:59 Stacey Simms 17:10 Dianne Mattisse 17:49 Stacey Simms 21:47 Dianne Mattisse 21:59 Stacey Simms 22:47 Dianne Mattisse 22:54 Stacey Simms 23:49 Dianne Mattisse 24:05 Stacey Simms 27:20 Dianne Mattisse 27:35 Stacey Simms 28:44 Dianne Mattisse 28:46 Stacey Simms 30:25 Dianne Mattisse 30:58 Stacey Simms 36:45 Dianne Mattisse 36:49 Stacey Simms 37:18 Dianne Mattisse 37:42 Stacey Simms 41:10 Dianne Mattisse 41:21
| |||
| In the News... Ingredients linked to T2D, genetic T1D research, new SGLT-2 guidelines and more! | 26 Apr 2024 | 00:05:51 | |
It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: A new study links emulsifiers, a common ingrediant, to type 2 diabetes, reserachers map out the pancreas in a new way that's already yielding new information, new guidliens about using GLP-1s and SGLT-2 medications with exisiting oral meds, genetic T1D studies and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com | |||
| "How can we continue to move T1D to the background?" Medtronic's Dr. Jennifer McVean | 23 Apr 2024 | 00:46:08 | |
This week, catching up with Medtronic's Senior Director of Global Medical Affairs Dr. Jennifer McVean. It's been one year since the 780G was approved in the US, what does the device – and its seven-day infusion set – look like in the real world. Plus, we have a big discussion about the future of type 1 diabetes – Dr. McVean has lead some significant trials – she lives with type 1 and has some big ideas about changes she'd like to see. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com
| |||
| Meet the newest insulin pump: all about "twiist" with Sequel CEO Alan Lotvin | 16 Apr 2024 | 00:44:03 | |
This week, the newest pump coming to the market is called the twiist. It's a very different shape – circular with a top half that twists off – with very different software – Tidepool Loop. The company behind this pump – they're called Sequel - wants to be different as well, hoping to offer solutions to bigger issue than basal and bolus rates. It's very ambitious and we have a wide ranging conversation about it all with Sequel's CEO Alan Lotvin This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Our episode about Tidepool Loop approval Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com | |||
| In the News... Dexcom-to-watch update, Wegovy studies, night time hypo research and more! | 12 Apr 2024 | 00:09:11 | |
It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: Dexcom launches direct-to-watch with the G7 in the UK and Ireland, more studies looking at heart benefits with Wegovy and diabetes, a new T1D study investigating an injectable to prevent overnight hypoglycemia, lobbying for Levimir, a ChatGPT diabetes diagnosis and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com | |||
| A new resource for exercise and T1D: DiabetesWise wants to help you move with confidence | 21 Oct 2025 | 00:32:43 | |
We all know how important exercise is for good health. And we all know how difficult exercise can be with type 1 diabetes. There's a new resource from some of the smartest people in our community. The folks at Diabetes Wise are adding exercise to their platform, which already has community and expert sourced information on devices. We're talking to the folks behind this move about what problems they want to solve, what's actually on the site and how to use it and how they manage their T1D while working out. You'll hear from Dr. Korey Hood and Dr. Dessi Zaharieva from DiabetesWise. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at an upcoming Moms' Night Out event! Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections. | |||
| The FDA took down this teen's free bolus calculator. He needs your help to bring it back. | 09 Apr 2024 | 00:33:49 | |
There used to be a lot of bolus calculators in the app store, maybe you've used one and haven't updated it in a while. Don't try now.. it's likely been pulled. Apple and the FDA are cracking down on this types of tools – no unreasonable, right? But surely there are more coming.. how hard can it be to create a simple insulin bolus calculator that's FDA approved, easy to find, easy to use, free, and doesn't require you buy anything else? Turns out, it's pretty darn hard. We're talking about that today with the inventor of such an app with an interesting story – he's still in high school. My guest this week was diagnosed with type 1 at age 13 – and while he and his family were calling in every blood sugar to help their doctor make adjustments, he thought there should be a better way. So Drew Mendelow created T1D1. I'll let him and his parents Laura and Mike tell you more about it and what makes it unique. It was recommended by his doctors to other patients and the word spread – they had tens of thousands of downloads. But in 2021, the FDA started cracking down on these kinds of apps and Apple pulled it. Drew has been working toward approval ever since and they're pretty close. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com | |||
| Diabetes Technology: Expectation vs Reality with Dr. Stephen Ponder | 02 Apr 2024 | 00:45:54 | |
Diabetes technology is getting better and better. We have automated insulin systems that link pumps and CGMs, and smart insulin pens that have precise calculations and reminders. It's been quite the evolution over the past few years! But outcomes – time in range, A1Cs, aren't exactly where experts thought they might be. I'm talking to Dr. Stephen Ponder about why that is, how a social media post he shared about this caused a strong reaction, and what does work for better long term outcomes. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com
| |||
| In the News... diabetes drug pricing, vial shortage, pump using Tidepool Loop cleared, insulin cows and more! | 29 Mar 2024 | 00:10:35 | |
It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: a new study shows that drugs like Ozempic can be produced for just a few dollars, we upate the insulin vial shortage Lilly announced, a new pump has been FDA cleared, a genetically modified cow can product human insulin, and more! Transcript and links below Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com
| |||
| Answering your questions about Tandem's new Mobi pump (and more) with Director of Product Marketing Ben Mar | 26 Mar 2024 | 00:37:28 | |
Approved last year, Tandem's Mobi is now widely available. We're getting an update from Ben Mar, Director of Product Marketing, on the features of the Mobi that make this tiny pump different and we look ahead to what Tandem is working on next. Ben also answers your questions about everything from algorithm updates, international access, and much more This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: | |||
| "It needs to be easier" - DIY pioneer Dana Lewis turns her attention to exercise and T1D | 19 Mar 2024 | 00:39:34 | |
This week, one of the pioneers of the DIY movement is turning her attention to exercise. Dana Lewis is partnering with other researchers to create a tool to help you make better and easier decisions around whatever workout you choose. There's a lot of variability here – big difference between say, weight lifting and long distance running – so this is no easy task. Dana will explain the tools they're using, the big goals here, and we get to catch up about what she's using these days to manage her life with T1D which now includes ultramarathoning. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Here's more about the Helmsley grants Stacey mentioned Here's more about T1Dexi Here are our previous episodes with Dana Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com | |||
| In the News... ATTD updates, new CGMs, drops for diabetes eye disease, scholarships and more! | 15 Mar 2024 | 00:08:45 | |
It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: The annual ATTD conference wraps up with news about CGMs, including new FDA approvals and a look at CGMs outside of the US, new eyedrops are being studied to treat diabetic eye disease and Beyond Type 1 opens applications for their annual Beyond Scholars. Transcript and links below Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com
| |||
| Behind the Wheel with T1D: Navigating Teen Driving and Diabetes | 12 Mar 2024 | 00:22:55 | |
Let's talk about driving with diabetes! Getting a driver's license as a teenager comes with enough challenges without type 1, but letting your child with T1D get behind the wheel is stressful, to say the least! I'm sharing what worked for us and expert advice that may help you and tips to let technology be your friend in the car. This is an excerpt of Stacey's book, "Still the World's Worst Diabetes Mom." It's the second book in her series. You can learn more about the books here on Amazon or on our website. Learn more about Moira McCarthy's book that Stacey mentions here. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com
| |||
| Addressing the "shocking" lack of research into T1D & periods - Tidepool's Period Project | 05 Mar 2024 | 00:42:24 | |
This week, addressing something that half of all people with diabetes experience but that there is woefully little information and study about. Why is there so little study about periods and type 1 diabetes? We're talking to two organizations who are teaming up to change that – but they need your help. We're talking about Tidepool's Period Project. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. You'll hear from Martina Rothenbühler, project leader data sciences and data protection officer at DCB, and Maya Friedman, founder of The Period Project at Tidepool. Learn more and sign up for the study here: Menstrual Cycle Study: Identifying changes in insulin sensitivity across the menstrual cycle in T1D - Diabetes Center Berne (dcberne.com) Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com | |||
| In the News... MicroGlucagon to speed up insulin, SGLT2 & false positive tests, FDA warns about non-invasive glucose monitors and more! | 01 Mar 2024 | 00:07:58 | |
It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: what is MicroGlucagon and how could it speed up existing rapid-acting insulin? SGLT2 medications may cause false positive alcohol tests, red light therapy for type 2 diabetes, research shows teens with type 2 might have a different kind of diabetes altogether, FDA warns against non-invasive glucose monitoring and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com | |||
| "It's the Chaos Lottery & our ticket got pulled" - Sarah Stewart Holland on parenting a child with T1D | 27 Feb 2024 | 01:00:33 | |
She calls it the Chaos Lottery – and says we all have different ways of dealing with what life throws our way. I'm talking to Sarah Stewart Holland, host of the huge podcast Pantsuit Politics about her family's journey with diabetes – her young son was diagnosed almost two years ago. She has a lot to say about parenting a child with a chronic condition – this is not her son's first serious diagnosis – and also about roles and identity and being a person without type 1 whos' raising a person with type 1. It's a lot and it's great. This interview was taped at Moms' Night Out Charlotte. I think it's a great example of what happens at these events. We moms aren't looking for perfection, we're looking for community. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out Here's the episode of Pantsuit Politics with Stacey Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com
| |||
| In the News.. COVID-19 & T1D, Ozempic Pill Progress, FDA to Consider Afrezza for kids, Faster Insulin, "Beyond Misconceptions," and More | 17 Oct 2025 | 00:09:13 | |
n the News.. COVID-19 & T1D, Ozempic Pill Progress, Faster Insulin, "Beyond Misconceptions," and More It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: A new study looks at the link between COVID-19 and very young children, Lilly moves ahead with their Ozempic oral pill, ultra-rapid insulin clears another hurdle, Beyond Type 1 launches a new campaign and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX https://www.scientificamerican.com/article/advances-in-type-1-diabetes-science-and-tech/ This article is part of "Innovations In: Type 1 Diabetes," an editorially independent special report that was produced with financial support from Vertex. XX More evidence linking COVID 19 to type 1 diabetes.. but still exactly why is a mystery. During the COVID-19 pandemic, there was an unexpected increase in the number of cases of type 1 diabetes in Sweden, particularly among children under 5 and young adult men. The infection accelerated the onset of diabetes among children between the ages of 5 and 9. The researchers looked at data from a 17-year period on the incidence of type 1 diabetes among all people under the age of 30 in Sweden. In addition, they compared the risk of developing diabetes among 720,000 individuals with positive COVID-19 tests against a control group of 3.5 million people. The findings are published in the journal Diabetologia. The number of diabetes cases increased by 12% in 2021 and 9% in 2022 compared with previous years. In 2023, the number of cases was back to a normal level. Despite this, the researchers cannot distinguish a clear connection between COVID-19 infection and diabetes, except for children between 5 and 9 years old. They had an increased risk of type 1 diabetes about one month after a COVID-19 infection even though their total risk did not increase. "However, it's clear that the COVID-19 vaccine can be ruled out as a cause of the increase in diabetes cases. The recommendation for the age group where we saw the strongest increase was not to get vaccinated. In addition, other studies on adults have shown that vaccination reduces the risk of developing type 1 diabetes after a COVID infection." https://medicalxpress.com/news/2025-10-diabetes-young-people-pandemic.html XX A new gene therapy approach aimed at protecting people with type 1 diabetes from developing diabetic kidney disease—a serious and common complication of the condition, has shown promising results in a University of Bristol study. Findings from this new study, published in Molecular Therapy, demonstrated a 64% reduction in a damage indicator for kidney disease, paving the way for a potential new treatment. The study, explored the potential of delivering a protein called VEGF-C directly into kidney cells. Previous studies have shown VEGFC could protect against kidney disease as it helps keep blood vessels in the kidney filter healthy, repairing early signs of diabetes-related kidney damage. https://medicalxpress.com/news/2025-10-gene-therapy-kidney-disease-diabetes.html XX The FDA has agreed to consider Afrezza inhaled insulin for children and teens. The company said in August that it submitted a supplemental Biologics License Application (sBLA) for Afrezza in the pediatric population and it's been assigned a decision deadline date of the end of May, 2026. Afrezza first recieved FDA approval for adults (age 18 and up) in June 2014 https://www.drugdeliverybusiness.com/fda-accepts-application-mannkind-inhaled-insulin-kids/ Update on inhaled insulin for kids.. in the open-label, randomized, phase 3 INHALE-1 clinical trial Afrezza demonstrated safe and effective replacement for rapid-acting meal insulin in children with type 1 diabetes (T1D and demonstrates comparable glycemic control to injected rapid-acting insulin. The INHALE-1 clinical trial assessed the safety and efficacy of Afrezza among children and adolescents with T1D, including a total of 230 patients aged 4 to 17 years. Researchers used basal injected insulin and randomly assigned inhaled insulin or rapid-acting analogue for meals, evaluating the change in hemoglobin A1c levels at 26 weeks. After completing 26 weeks of randomly assigned treatment with either Afrezza or rapid-acting insulin injections combined with basal insulin, participants continued receiving the inhaled insulin until week 52 for an extension phase to evaluate the safety and effectiveness of Afrezza with continued use.1,2 XX Eli Lilly released the results of two new Phase 3 trials of an experimental GLP-1 pill that the company says could become a "foundational treatment" for type 2 diabetes. The Indianapolis-based drugmaker plans to submit global regulatory applications for orforglipron in the treatment of type 2 diabetes next year. The company said it will seek approval of the drug as an obesity medication by the end of 2025. Lilly is trying to build on the success of its Mounjaro/Zepbound franchise by offering patients a pill instead of an injection. But the company is trailing behind rival Novo Nordisk in developing an oral alternative, and data released so far has raised some skepticism among investors. A study released in August showed that orforglipron could help patients lose an average of about 12% of their body weight. Wall Street had been expecting more; Lilly's injectable drug Zepbound produced weight loss of as much as 21%, and Novo Nordisk has achieved 15% weight loss percentages for both oral and injectable versions of its Wegovy medication.
https://www.fiercebiotech.com/biotech/eli-lillys-orforglipron-bests-farxiga-padding-oral-glp-1-case-pair-phase-3-diabetes-wins
XX XX UF Health Cancer Center researchers have found a surprising culprit behind common health problems such as obesity, diabetes and fatty liver disease: silent genetic glitches in the blood system that occur naturally as people age. The findings, published in the Journal of Clinical Investigation, mean that in the future, simple blood tests could be developed to identify people most at risk early on, helping prevent chronic illnesses and cancer through strategies like diet or lifestyle changes. As people age, stem cells in the bone marrow that produce blood cells gradually accumulate mutations in their DNA. Most mutations don't cause any issues, but sometimes blood stem cells with a mutation can start crowding out their peers. Called clonal hematopoiesis, this condition affects about 10% of older people and is associated with an increased risk of blood cancers like leukemia. It's also linked to a higher risk of obesity and diabetes. But the prevailing thinking was that obesity and related conditions promoted blood cell changes, not the other way around. The new study reverses that. The implications could be far-reaching, particularly as obesity has now overtaken smoking as the most significant and preventable risk factor for cancer. The team is studying how the mutations drive disease. Next, they plan to test how drugs like those commonly used to treat diabetes and new popular weight loss drugs might help reverse or prevent diseases caused by blood cell changes. https://medicalxpress.com/news/2025-10-hidden-blood-mutations-obesity-diabetes.html XX A new ultra rapid insulin continues to move forward. A phase 3 clinical trial of BioChaperone Lispro (liss-pro) conducted in China found it safe and effective compared with Humalog along with a significant reduction of the rise of blood glucose after a test meal.
These results complete and confirm the positive outcomes previously obtained with THDB0206 injection in people with Type 2 Diabetes It combines Adocia's proprietary BioChaperone® technology with insulin lispro, the active ingredient in the standard of care, Humalog® (Eli Lilly).
This innovative formulation acts significantly faster https://pharmatimes.com/news/ultra-rapid-insulin-shows-promise-in-phase-3-trial-for-type-1-diabetes/
Poor blood sugar control in adolescent patients with type 1 diabetes (T1D) may be associated with a higher risk of neuropathy in adulthood, according to recent research from the University of Michigan.1 The study included children diagnosed with T1D between 1990-1992 who were recruited into the Cognition and Longitudinal Assessment of Risk Factors over 30 Years cohort study in Australia. Investigators collected HbA1c from medical records, and microvascular complications were assessed through self-reports, clinical screenings, retinal photographs, and urinary albumin-creatinine testing.3
A total of 30 children were recruited from the original cohort with a mean diagnosis age of 2.9 years. After an average of 29.7 years (standard deviation [SD]: 3.9 years), 33% of participants (n = 13) developed neuropathy, 63% (n = 19) developed diabetes-related eye disease, and 10% (n = 3) developed neuropathy.3 Mean HbA1c estimates during adolescence (9% [74.9 mmol/mol]; 95% CI, 8.6-9.3 [70.5-78.1]) were substantially higher than childhood (8.2% [66.1 mmol/mol]; 95% CI, 7.8-8.5 [61.7-69.4]; P <.001) and adulthood (8.2% [66.1 mmol/mol]; 95% CI, 7.8-8.5 [61.7-69.4]). Investigators also noted a significant association between greater deviation from mean childhood HbA1c and increased neuropathy risk (RRR, 7.8; 95% CI, 1.1-57.4; P = .009), but not retinopathy or nephropathy (P ≥.06).3 Ultimately, although they noted other potential influences for future complication risks, investigators determined that adolescent hyperglycemia leads to higher neuropathy risk in adulthood, regardless of preexisting childhood control. The team urges adolescent glycemic management, noting that patients with adolescent hyperglycemia may require more support in transitioning to adult care. XX Blue Circle Health has expanded to five more states: Massachusetts, Connecticut, Pennsylvania, Virginia, and Kentucky! This will bring the total number of states served to 16 and we are planning additional expansion prior to the end of the calendar year. Free, expert clinical care, education, and support for adults living with type 1 diabetes Blue Circle Health is a nonprofit organization with a 6-month program for adults 18+ living with type 1 diabetes. We offer free, personalized, virtual clinical care, education, and support — thanks to generous funding from The Leona M. and Harry B. Helmsley Charitable Trust. As a reminder, the program is currently active in 11 other states: Alabama, Louisiana, Mississippi, Florida, Missouri, Iowa, Ohio, Vermont, New Hampshire, Maine, and Delaware to adults 18+ with type 1 diabetes! https://www.bluecirclehealth.org/ XX O'Reilly Automotive Inc. is suing major pharmacy benefit managers (PBMs) and insulin manufacturers, alleging collusion to inflate insulin prices. The lawsuit accuses CVS Caremark, Express Scripts, Optum Rx, Eli Lilly, Novo Nordisk and Sanofi of violating the RICO Act. O'Reilly claims the companies conspired to control insulin prices, leading to increases of up to 1000%. O'Reilly Automotive Inc. provides health benefits to approximately 45,000 members O'Reilly is requesting treble damages — three times the amount of actual damages — as well as restitution and damages available under state laws, punitive damages and to recover the costs of its suit. https://www.news-leader.com/story/news/health/2025/08/07/oreilly-automotive-sues-insulin-producers-prescription-managers-inflating-prices/85528977007/ XX Nobel Prize
XX On social media, Tandem Diabetes Care (Nasdaq:TNDM) said the launch of a new integration for its insulin pump system is near. "It's almost here! The t:slim X2 insulin pump integration with the FreeStyle Libre 3 Plus sensor, the world's smallest continuous glucose monitor, is coming soon," Tandem wrote on LinkedIn.
Tandem announced that it was pairing its t:slim X2 automated insulin delivery system with Libre 3 Plus in June. At the time, the company said it had already initiated an early access program for integration in the U.S. with plans to scale availability in the second half of 2025.
On Tandem's website, it says the pump will integrate with the FreeStyle Libre 3 Plus "by the end of 2025."
The pending rollout would provide the latest pairing of automated insulin delivery (AID) and continuous glucose monitor (CGM) technologies between the companies. They announced the integration of FreeStyle Libre 2 Plus CGM into the t:slim X2 insulin pump in January 2024. Just last week, the companies announced the future pairing of Tandem systems with Abbott's under-development dual glucose-ketone sensor.
Abbott's FreeStyle Libre 3 Plus is the company's latest-generation CGM designed for insulin pump integration. Its readings every minute can help insulin pumps adjust to users' needs. The system also offers a 15-day wear time.
t:slim X2, powered by Control-IQ+ technology, has an advanced hybrid closed-loop automated insulin delivery feature. It predicts and helps prevent high and low blood sugar. Control-IQ leads to improved time in range throughout the day and night. Tandem unveiled the next-generation algorithm earlier this year. https://www.drugdeliverybusiness.com/tandem-abbott-libre-3-coming-soon/ XX New campaign from Beyond Type 1 about smashing misconceptions about all types of diabetes featuring a video with Nick Jonas. I was really happy to see that this is a video that uses a lot of humor as well as a bunch of real life amazing people with type 1 who aren't all celebrities. You'll probably recognize a few and some have been on the podcast. Very well done and worth sharing. https://www.youtube.com/watch?v=SnJQocFIutY https://beyondtype1.org/go-beyond-misconceptions-stigmas-diabetes/ | |||
| "I needed to take my own advice" - Catching up with advocate Chris Ruden | 20 Feb 2024 | 00:32:45 | |
We are far away from New Year's resolutions and it's feeling a little wintry and dreary around here. Good time to get some motivation and check in with Chris Ruden. Many of you know likely know Chris – who lives with type 1 - from his appearance on the Titan games, his bodybuilding videos or maybe it's the videos where he shows his prosthetic hand. Chris has a lot to say about where all of that has brought him and what's different for him now. He also uses the implantable Eversense CGM – always a lot of questions about that, so I asked him all about it. More about Friends for Life here This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com | |||
| In the News.. Tandem Mobi released, surprising outcomes for type 2 surgery, exercise and diabetes studies, T1D at the Super Bowl, and more! | 16 Feb 2024 | 00:08:41 | |
It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: Tandem announces it's taking orders and starting to ship the Mobi pump, Insulet gets European approval for the Abbott Libre integration with Omnipod 5, new study looks at type 2 remission and gastric bypass surgery, one type of medication seems to do a much better job preventing kidney stones in people with type 2, big new grant to look at exercise and type 1 and a look back at diabetes at the Super Bowl. Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com
| |||
| Dexcom's Jake Leach on a new CGM for type 2, updates on G6, G7 and more! | 13 Feb 2024 | 00:28:55 | |
This week, we get an update from Dexcom. Chief Operating Officer Jake Leach talks about their soon to be launched CGM for people with type 2. It's called Stelo and it's front of the FDA right now. We also answer a lot of your questions about G6, G7, interoperability, connectivity and what's next. Some information on Stelo: https://diatribe.org/new-dexcom-cgm-people-type-2-diabetes-not-using-insulin Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode summary (AI generated) A new CGM product for people with type 2 diabetes. CGM for type 2 diabetes and payer coverage. CGM access, naming, and interoperability. G7 features and enhancements. Dexcom's CGM technology and its potential for more widespread access.
| |||